

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2022

Commission File Number: 001-40618

**Stevanato Group S.p.A.**

(Translation of registrant's name into English)

Via Molinella 17  
35017 Piombino Dese – Padua  
Italy

(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

---

Stevanato Group S.p.A.

**Interim condensed consolidated financial statements  
for the three and the nine months ended September 30, 2022**

**Table of Contents**

	<b>Page</b>
<u>PART I - FINANCIAL INFORMATION</u>	1
<u>Item 1. Financial Statements</u>	1
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	36
<u>Item 3. Quantitative and Qualitative Disclosure About Market Risk</u>	56
<u>Item 4. Controls and Procedures</u>	61
<u>PART II - OTHER INFORMATION</u>	62
<u>Item 1. Legal Proceedings</u>	62
<u>Item 1.A Risk Factors</u>	62
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	62
<u>Item 3. Defaults Upon Senior Securities</u>	62
<u>Item 5. Other Information</u>	62
<u>SIGNATURES</u>	63

---

## CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 6-K contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group”, the “Company” and, together with its subsidiaries, the “Group”). These forward-looking statements include, or may include, words such as “raising”, “believe”, “potential”, “increased”, “future”, “remain”, “growing”, “expect”, “foreseeable”, “expected”, “to be”, “includes”, “estimated”, “assumes”, “would provide”, “anticipate”, “will”, “plan”, “may”, “forecast”, and other similar terminology. Forward-looking statements contained in this report include, but are not limited to, statements about: our future financial performance, including our revenue, operating expenses and our ability to maintain profitability and operational and commercial capabilities; our expectations regarding the development of our industry and the competitive environment in which we operate; the expansion of our plants and our expectations to increase production capacity; the global supply chain and our committed orders; the global response to SARS-CoV-2 coronavirus (“COVID-19”) and our role in it; our geographical and industrial footprint; and our goals, strategies and investment plans. These statements are neither promise nor guarantee but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Stevanato Group actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, inflation, potential negative developments in the COVID-19 pandemic, the impact of the conflict between Russia and Ukraine, supply chain and logistical challenges and other negative developments in Stevanato Group’s business or unfavorable legislative or regulatory developments. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: (i) our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation; (ii) we must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors to remain competitive; (iii) our backlog might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our backlog; (iv) if we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected; (v) we are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth; (vi) our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers; (vii) our business, financial condition and results of operations depend upon the availability and price of high-quality materials and energy supply and our ability to contain production costs; (viii) the current conflict between Russia and Ukraine and the financial and economic sanctions imposed by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia and Belarus may negatively impact our ability to source gas at commercially reasonable terms or at all and could have a material adverse effect on our operations; (ix) significant interruptions in our operations could harm our business, financial condition and results of operations; (x) as a consequence of the COVID-19 pandemic, sales of syringes and vials to and for vaccination programs globally increased resulting in a revenue growth acceleration. The demand for such products may shrink, if the need for COVID-19 related solutions declines; (xi) our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows; (xii) we may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors; (xiii) our global operations are subject to international market risks that may have a material effect on our liquidity, financial condition, results of operations and cash flows; (xiv) we are required to comply with a wide variety of laws and regulations and are subject to regulation by various federal, state and foreign agencies; (xv) if relations between China and the United States deteriorate, our business in the United States and China could be materially and adversely affected; and (xvi) Cyber security risks and the failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions, could result in damage to our reputation, data integrity and/or subject us to costs, fines or lawsuits under data privacy or other laws or contractual requirements. This list is not exhaustive. We caution you therefore against relying on these forward-looking statements and we qualify all of our forward-looking statements by these cautionary statements.

These forward-looking statements speak only as at their dates. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible to predict all of these factors. Further, the Company cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statements.

For a description of certain additional factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, refer to the risk factors discussed under “Item 1A. Risk Factors” below and “Risk Factors” in our Annual Report on Form 20-F/A for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission on April 5, 2022.

---

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

Stevanato Group S.p.A.

Interim consolidated income statements

for the three and the nine months ended September 30, 2022 and 2021

(Unaudited)

	Notes	For the three months ended September 30,		For the nine months ended September 30,	
		2022	2021	2022	2021
		(EUR thousand)		(EUR thousand)	
Revenues	9	245,261	214,535	691,582	611,348
Cost of sales	10	167,722	151,262	472,022	418,976
<b>Gross Profit</b>		<b>77,539</b>	<b>63,273</b>	<b>219,560</b>	<b>192,372</b>
Other operating income	11	3,447	1,725	12,126	7,206
Selling and Marketing expenses	12	5,898	4,707	17,821	15,999
Research and Development expenses	12	7,614	7,393	23,797	20,110
General and Administrative expenses	12	19,919	24,665	60,758	44,702
<b>Operating Profit</b>		<b>47,554</b>	<b>28,233</b>	<b>129,309</b>	<b>118,767</b>
Finance income	13	6,736	2,066	17,235	6,381
Finance expense	14	8,250	8,032	22,734	13,681
Share of profit of an associate		—	150	—	547
<b>Profit Before Tax</b>		<b>46,040</b>	<b>22,417</b>	<b>123,810</b>	<b>112,014</b>
Income taxes	15	9,753	3,781	29,135	22,347
<b>Net Profit</b>		<b>36,287</b>	<b>18,636</b>	<b>94,675</b>	<b>89,667</b>
<b>Net Profit attributable to:</b>					
Equity holders of the parent		36,215	18,655	94,469	89,647
Non-controlling interests		72	(19)	206	20
		<b>36,287</b>	<b>18,636</b>	<b>94,675</b>	<b>89,667</b>
<b>Earnings per share</b>					
Basic earnings per common share (in EUR)	16	0.14	0.07	0.36	0.36
Diluted earnings per common share (in EUR)	16	0.14	0.07	0.36	0.36

The accompanying notes are an integral part of the Interim Condensed Consolidated Financial Statements

**Stevanato Group S.p.A.**  
**Interim consolidated statements of comprehensive income**  
for the three and the nine months ended September 30, 2022 and 2021  
(Unaudited)

	Notes	For the three months ended September 30,		For the nine months ended September 30,	
		2022 (EUR thousand)	2021 (EUR thousand)	2022 (EUR thousand)	2021 (EUR thousand)
<b>Net Profit</b>		<b>36,287</b>	<b>18,636</b>	<b>94,675</b>	<b>89,667</b>
Gains/(losses) from remeasurement of employee defined benefit plans		153	13	1,033	200
Tax effect relating to those components of OCI		(37)	(1)	(248)	(46)
<b>Other comprehensive income (loss) that will not be classified subsequently to profit or loss</b>		<b>116</b>	<b>12</b>	<b>785</b>	<b>154</b>
Exchange difference on translation of foreign operations	24	8,355	(350)	26,766	7,537
Changes in the fair value of cash flow hedging instruments		2,376	290	7,022	1,602
Tax effect relating to those components of OCI		(570)	(70)	(1,685)	(384)
<b>Other comprehensive income (loss) that will be classified subsequently to profit or loss</b>		<b>10,161</b>	<b>(129)</b>	<b>32,103</b>	<b>8,754</b>
<b>Total other comprehensive income (loss), net of tax</b>		<b>10,278</b>	<b>(117)</b>	<b>32,889</b>	<b>8,908</b>
<b>Total Comprehensive Income</b>		<b>46,565</b>	<b>18,519</b>	<b>127,564</b>	<b>98,576</b>
<b>Attributable to:</b>					
Equity holders of the parent		46,496	18,542	127,333	98,546
Non-controlling interests		69	(24)	231	30
		<b>46,565</b>	<b>18,519</b>	<b>127,564</b>	<b>98,576</b>

The accompanying notes are an integral part of the Interim Condensed Consolidated Financial Statements

**Stevanato Group S.p.A.**  
**Interim consolidated statements of financial position**  
as at September 30, 2022 and at December 31, 2021  
(Unaudited)

		At September 30, 2022	At December 31, 2021
		(EUR thousand)	
<b>Assets</b>	<b>Notes</b>		
<b>Non-current assets</b>			
Goodwill		47,243	47,243
Other intangible assets	17	34,446	31,928
		21,035	22,690
Right of Use assets	19		
Property, plant and equipment	18	570,178	392,717
Financial assets - investments FVTPL		1,096	1,084
Other non-current financial assets	20	913	1,334
Deferred tax assets		65,701	55,877
		<b>740,612</b>	<b>552,873</b>
<b>Current assets</b>			
Inventories	21	218,052	148,917
Contract assets	22	91,711	62,133
Trade receivables	22	204,197	165,259
Other current financial assets	20	33,419	27,217
Tax receivables	23	34,787	25,063
Other receivables		45,523	26,341
Cash and cash equivalents		259,929	411,039
		<b>887,618</b>	<b>865,969</b>
<b>Total assets</b>		<b>1,628,230</b>	<b>1,418,842</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital	24	21,698	21,698
Reserves and Retained Earnings	24	847,131	686,055
Net profit attributable to equity holders of the parent		94,469	134,321
<b>Equity attributable to equity holders of the parent</b>		<b>963,298</b>	<b>842,074</b>
Non-controlling interests		(184)	(415)
<b>Total equity</b>		<b>963,114</b>	<b>841,659</b>
<b>Non-current liabilities</b>			
Non-current financial liabilities	25	170,817	202,296
Employees benefits	27	7,950	11,853
Provisions	28	4,912	3,499
Deferred tax liabilities		21,693	19,105
Other non-current liabilities	29	15,998	1,808
		<b>221,370</b>	<b>238,561</b>
<b>Current liabilities</b>			
Current financial liabilities	25	72,911	46,195
Trade payables	30	203,076	164,787
Contract liabilities	31	23,111	18,771
Advances from customers	31	26,793	23,616
Tax payables	23	43,073	19,440
Other liabilities	30	74,782	65,813
		<b>443,746</b>	<b>338,622</b>
<b>Total liabilities</b>		<b>665,116</b>	<b>577,183</b>
<b>Total equity and liabilities</b>		<b>1,628,230</b>	<b>1,418,842</b>

The accompanying notes are an integral part of the Interim Condensed Consolidated Financial Statements

Stevanato Group S.p.A.

Interim consolidated statements of changes in equity

for the nine months ended September 30, 2022 and 2021

(Unaudited)

	Note s	Share capital	Share Premiu m Reserve	Treasur y shares	Cash flow hedge reserve	Reserve for actuarial gains / (losses) (EUR thousand)	Foreign currency translatio n reserve	Retaine d earnin g s and other reserve	Equity attributabl e to equity holders of the parent	Non- controllin g interests	Total equity
<b>At January 1, 2022</b>		<b>21,698</b>	<b>389,312</b>	<b>(27,740)</b>	<b>(1,277)</b>	<b>(745)</b>	<b>(22,680)</b>	<b>483,506</b>	<b>842,074</b>	<b>(415)</b>	<b>841,659</b>
Other comprehensive income	24	—	—	—	5,337	785	26,741	—	32,863	25	32,888
Net profit		—	—	—	—	—	—	94,469	94,469	206	94,675
<b>Total comprehensive income</b>		<b>—</b>	<b>—</b>	<b>—</b>	<b>5,337</b>	<b>785</b>	<b>26,741</b>	<b>94,469</b>	<b>127,332</b>	<b>231</b>	<b>127,563</b>
Dividends	24	—	—	—	—	—	—	(13,500)	(13,500)	—	(13,500)
Other		—	—	—	—	—	—	7,391	7,391	—	7,391
<b>Total effects</b>		<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>(6,109)</b>	<b>(6,109)</b>	<b>—</b>	<b>(6,109)</b>
<b>At September 30, 2022</b>		<b>21,698</b>	<b>389,312</b>	<b>(27,740)</b>	<b>4,060</b>	<b>40</b>	<b>4,061</b>	<b>571,866</b>	<b>963,298</b>	<b>(184)</b>	<b>963,114</b>

The accompanying notes are an integral part of the Interim Condensed Consolidated Financial Statements

	Note	Share capital	Share Premium Reserve	Treasury shares	Cash flow hedge reserve	Reserve for actuarial gains / (losses) (EUR thousand)	Foreign currency translation reserve	Retained earnings and other reserve	Equity attributable to equity holders of the parent	Non-controlling interests	Total equity
<b>At January 1, 2021</b>		<b>20,002</b>	<b>—</b>	<b>(26,189)</b>	<b>(3,345)</b>	<b>(675)</b>	<b>(34,911)</b>	<b>355,613</b>	<b>310,495</b>	<b>(355)</b>	<b>310,140</b>
Other comprehensive income	24	—	—	—	1,217	154	7,527	—	8,898	10	8,908
Net profit		—	—	—	—	—	—	89,647	89,647	20	89,667
<b>Total comprehensive income</b>		<b>—</b>	<b>—</b>	<b>—</b>	<b>1,217</b>	<b>154</b>	<b>7,527</b>	<b>89,647</b>	<b>98,546</b>	<b>30</b>	<b>98,576</b>
Dividends	24	—	—	—	—	—	—	(11,200)	(11,200)	—	(11,200)
Capital increase		1,696	410,563	—	—	—	—	—	412,259	—	412,259
Accessory costs to the capital increase		—	(27,849)	—	—	—	—	—	(27,849)	—	(27,849)
Taxes relating to capital increase costs		—	6,684	—	—	—	—	—	6,684	—	6,684
Other		—	—	(1,551)	—	—	—	4,434	2,883	—	2,883
<b>Total effects</b>		<b>1,696</b>	<b>389,397</b>	<b>(1,551)</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>(6,766)</b>	<b>382,777</b>	<b>—</b>	<b>382,777</b>
<b>At September 30, 2021</b>		<b>21,698</b>	<b>389,397</b>	<b>(27,740)</b>	<b>(2,128)</b>	<b>(521)</b>	<b>(27,384)</b>	<b>438,496</b>	<b>791,817</b>	<b>(325)</b>	<b>791,492</b>

The accompanying notes are an integral part of the Interim Condensed Consolidated Financial Statements



**Stevanato Group S.p.A.**  
**Interim consolidated statements of cash flows**  
for the nine months ended September 30, 2022 and 2021  
(Unaudited)

	For the nine months ended September 30,	
	2022	2021
	(EUR thousand)	
Notes		
<b>Operating activities</b>		
<b>Profit before tax</b>	<b>123,810</b>	<b>112,014</b>
Adjustments:		
Depreciation and impairment of property, plant and equipment	37,036	31,011
Amortization of intangible assets and Right of Use	10,717	10,277
Allowance for doubtful accounts	565	332
Net finance expense/ (income)	7,823	8,633
Share of profit or loss of associated companies	—	(547)
(Gain)/Loss from the disposal of non-current assets	(119)	(16)
Change in other provisions and in employee benefits	(7,768)	(8,791)
Other non-cash expenses, net	1,385	(769)
Working capital changes:		
- inventories and contract assets	(95,478)	(33,794)
- trade receivables and other assets	(60,929)	(44,826)
- trade payables, contract liabilities, advances and other liabilities	52,020	27,664
Interest paid	(2,455)	(3,135)
Interest received	486	465
Income tax paid	(23,497)	(20,617)
<b>Cash Flow from operating activities</b>	<b>43,594</b>	<b>77,901</b>
<b>Cash Flow from investing activities</b>		
Purchase of property, plant and equipment	(167,139)	(71,371)
Proceeds from sale of property plant and equipment	521	34
Purchase of intangible assets	(7,786)	(3,405)
Investment in financial assets	257	(589)
<b>Net cash flows used in investing activities</b>	<b>(174,146)</b>	<b>(75,332)</b>
<b>Cash Flow from financing activities</b>		
Net proceeds from and fees for IPO	—	380,202
Acquisition of non-controlling interests	—	(1,103)
Dividends paid	(13,500)	(11,200)
Payment of principal portion of lease liabilities	(4,925)	(4,902)
Proceed from loans	12,399	8,050
Repayments of loans	(19,904)	(77,805)
Decrease in other current financial activities	—	14,032
<b>Net cash flows from/(used in) financing activities</b>	<b>(25,930)</b>	<b>307,275</b>
<b>Net change in cash and cash equivalents</b>	<b>(156,483)</b>	<b>309,844</b>
Net foreign exchange difference	5,373	2,531
<b>Cash and cash equivalents at January 1</b>	<b>411,039</b>	<b>115,599</b>
<b>Cash and cash equivalents at September 30</b>	<b>259,929</b>	<b>427,974</b>

The accompanying notes are an integral part of the Interim Condensed Consolidated Financial Statements

### 1. Corporate information

Stevanato Group is headquartered in Italy and its registered office is located at via Molinella 17, Piombino Dese (Padova, Italy). The Group is active in the design, production and distribution of products and technology to provide integrated solutions primarily for the bio-pharma, pharmaceutical and healthcare industries. The Group's continuous investments, advancement of technology in primary packaging, strong reputation and complementary acquisitions, have helped it become a global player in the bio-pharma industry. The Company's principal products are drug containment and primary packaging solutions, drug delivery systems, medical devices, in-vitro diagnostics, analytical services, visual inspection machines, assembling and packaging machines and glass forming machines.

The Group has nine production plants for manufacturing and assembly of bio-pharma, pharmaceutical and healthcare products (in Italy, Germany, Slovakia, Brazil, Mexico, China, and the United States), five plants for the production of machinery and equipment (in Italy and Denmark), two sites for analytical services (in Italy and the United States) and two commercial offices (in Japan and the United States). Further, on October 4, 2021, the Group announced the start of construction of a new North American EZ-fill® hub in Fishers, Indiana, United States. On March 10, 2022, the Group announced the acquisition of a new facility in Zhangjiagang, China which will undergo renovations and serve as its Asia Pacific regional hub for both EZ-fill® and standard products. On May 31, 2022, the Group announced the acquisition of a new facility in Cisterna di Latina, Italy which will undergo renovations for the expansion of capacity for the Company's EZ-fill® product portfolio. The Group is also investing in the expansion of production facilities in Piombino Dese, Italy, where construction of a new building is underway to also support the expansion of the Company's EZ-fill® product portfolio. The expansion of the Group's global footprint is in response to rising demand for premium high value solutions products and it will diversify production, improve proximity to customers and allow the Group to provide services in more than 70 countries worldwide.

Stevanato Group S.p.A. is controlled by Stevanato Holding S.r.l. which holds 78.03% of its share capital. On July 16, 2021, Stevanato Group began trading on the New York Stock Exchange under the symbol STVN.

### 2. Authorization of interim condensed consolidated financial statements and compliance with international financial reporting standards

These Interim Condensed Consolidated Financial Statements of Stevanato Group S.p.A. were authorized for issuance November 4, 2022 and have been prepared in accordance with *IAS 34 - Interim Financial Reporting*. These Interim Condensed Consolidated Financial Statements should be read in conjunction with the Group's consolidated financial statements at and for the year ended December 31, 2021 (the "Consolidated Financial Statements"), which have been prepared in accordance with *International Financial Reporting Standards (IFRS)* as issued by the International Accounting Standards Board ("IASB").

### 3. Basis of preparation for interim condensed consolidated financial statements

The preparation of the Interim Condensed Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities as well as disclosures of contingent liabilities. If in the future such estimates and assumptions, which are based on management's best judgment at the date of these Interim Condensed Consolidated Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change. Reference should be made to the section "Use of estimates" in the Consolidated Financial Statements for a detailed description of the more significant valuation procedures used by the Group.

Moreover, in accordance with *IAS 34*, certain valuation procedures, in particular those of a more complex nature regarding matters such as any impairment of non-current assets, are only carried out in full during the preparation of the annual consolidated financial statements, when all the related information necessary is available, other than in the event that there are indications of impairment, in which case an immediate assessment is required.

Similarly, the actuarial valuations that are required for the determination of employee benefit provisions are also usually carried out during the preparation of the annual consolidated financial statements, except in the event of significant market fluctuations or significant plan amendments, curtailments or settlements. *IAS 34* also requires the disclosure of the nature and amount of items affecting net income that are unusual due to their nature, size or significance.

These Interim Condensed Consolidated Financial Statements consider that the Group publishes quarterly interim financial statements. The Group has prepared the financial statements on the basis that it will continue to operate as a going concern. The Group's Audit Committee, together with the Board of Directors, consider that there are no material uncertainties that may cast significant doubts over this assumption. The Board of Directors have formed a judgement that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and not less than 12 months from the end of the reporting period.

As the Group is not including the full set of disclosures, as required in a complete set of financial statements, the interim financial statements of the Group are regarded as 'condensed', as per *IAS 34*.

#### **New standards, amendments and interpretations**

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2021, except for the adoption of new standards effective as of January 1, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

The following amendments and interpretations were adopted for the first time in 2022 and did not have a material impact on the interim condensed consolidated financial statements of the Group:

- Amendments to *IFRS 3 – Reference to the Conceptual Framework*,
- Amendments to *IAS 16 – Property, Plant and Equipment: Proceeds before Intended Use*,
- Amendments to *IAS 37 – Onerous Contracts – Costs of Fulfilling a Contract*.

#### **Amendments to IFRS 3 - Reference to the Conceptual Framework**

In May 2020, the IASB issued Amendments to *IFRS 3 - Business Combinations - Reference to the Conceptual Framework*. The amendments are intended to replace a reference to the Framework for the Preparation and Presentation of Financial Statements, issued in 1989, with a reference to the Conceptual Framework for Financial Reporting issued in March 2018 without significantly changing its requirements. The IASB also added an exception to the recognition principle of *IFRS 3* to avoid the issue of potential 'day 2' gains or losses arising for liabilities and contingent liabilities that would be within the scope of *IAS 37* or *IFRIC 21 - Levies*, if incurred separately. At the same time, the IASB decided to clarify existing guidance in *IFRS 3* for contingent assets that would not be affected by replacing the reference to the Framework for the Preparation and Presentation of Financial Statements. The amendments are effective for annual reporting periods beginning on or after January 1, 2022 and apply prospectively. The amendments did not have a material impact on the Group.

#### **Amendments to IAS 16 - Property, Plant and Equipment: Proceeds before Intended Use**

In May 2020, the IASB issued Amendments to *IAS 16 - Property, Plant and Equipment - Proceeds before Intended Use*, which prohibits entities deducting from the cost of an item of property, plant and equipment, any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognizes the proceeds from selling such items, and the costs of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and must be applied retrospectively to items of property, plant and equipment made available for use on or after the beginning of the earliest period presented when the entity first applies the amendment. The amendments did not have a material impact on the Group.

#### **Amendments to IAS 37 - Onerous Contracts - Costs of Fulfilling a Contract**

In May 2020, the IASB issued Amendments to *IAS 37 - Onerous Contracts* to specify which costs an entity needs to include when assessing whether a contract is onerous or loss-making. The amendments apply a "directly related cost approach".

The costs that relate directly to a contract to provide goods or services include both incremental costs and an allocation of costs directly related to contract activities. General and Administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The amendments are effective for annual reporting periods beginning on or after January 1, 2022. The Group will apply these amendments to contracts for which it has not yet fulfilled all its obligations at the beginning of the annual reporting period in which it first applies the amendments. The amendments did not have a material impact on the Group.

#### **New standards, amendments and interpretations not yet effective**

##### **Amendments to IAS 1 - Classification of Liabilities as Current or Non-current**

In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:

- What is meant by a right to defer settlement.
- That a right to defer must exist at the end of the reporting period.
- That classification is unaffected by the likelihood that an entity will exercise its deferral right.
- That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification.

The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and must be applied retrospectively. The Group is currently assessing the impact the amendments will have on current practice, monitoring the IFRS Interpretations Committee's discussions, and whether existing loan agreements may require renegotiation.

##### **Amendments to IAS 8 - Accounting Policies, Changes to Accounting Estimates and Errors**

On February 12, 2021, the IASB issued amendments to IAS 8 Accounting Policies, Changes to Accounting Estimates and Errors, in which it introduces a new definition of "accounting estimates". The amendments are designed to clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. The amendments become effective for annual reporting periods beginning on or after January 1, 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. The amendments are not expected to have a material impact on the Group.

##### **Amendments to IAS 1 - Presentation of Financial Statements**

In February 2021, the IASB issued amendments to IAS 1 Presentation of Financial Statements in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The IASB also issued amendments to IFRS Practice Statement 2 Making Materiality Judgements (PS) to support the amendments in IAS 1 by explaining and demonstrating the application of the 'four-step materiality process' to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their 'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments to IAS 1 are applicable for annual periods beginning on or after January 1, 2023. The amendments are not expected to have a material impact on the Group.

##### **Amendments to IAS 12 - Deferred Tax related to Assets and Liabilities arising from a Single Transaction**

In May 2021, the IASB issued amendments to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction, that clarify the accounting of deferred tax on transactions such as leases and decommissioning obligations. The main change in Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12) is an exemption from the initial recognition exemption provided in IAS 12.15(b) and IAS 12.24. Accordingly, the initial recognition exemption does not apply to transactions in which equal amounts of deductible and taxable temporary differences arise on initial recognition (this is also explained in the newly inserted paragraph IAS 12.22A). The amendments to IAS 12 are applicable for annual periods beginning on or after January 1, 2023. The amendments are not expected to have a material impact on the Group.

#### 4.Scope of consolidation

Stevanato Group S.p.A. is the parent company of the Group and it holds, directly and indirectly, interests in the Group's main operating companies. There are no changes in the scope of consolidation for the periods presented in this Interim Report and the Group's scope of consolidation is as follows:

#### Subsidiaries

The interim condensed consolidated financial statements of the Group include the following companies directly or indirectly controlled:

Name	Segment	Description	Country of incorporation	Type of control	% equity interest	
					Sep. 30, 2022	Dec. 31, 2021
Nuova Ompi S.r.l.	Biopharmaceutical	Production of drug containment systems and development of integrated solutions for the pharmaceutical industry	Italy	Direct	100%	100%
Spami S.r.l.	Engineering	Production plant and machinery	Italy	Direct	100%	100%
Stevanato Group International a.s.	Holding	Service/Subholding company	Slovakia	Direct	100%	100%
Medical Glass a.s.	Biopharmaceutical	Production of drug containment systems	Slovakia	Indirect	99.74%	99.74%
Stevanato Group N.A. S. de RL de CV	Biopharmaceutical	Service company	Mexico	Indirect	100%	100%
Ompi N.A. S. de RL de CV	Biopharmaceutical	Production of drug containment systems	Mexico	Direct	30.76%	30.76%
				Indirect	69.24%	69.24%
Ompi of America inc.	Biopharmaceutical	Sale of drug containment systems and analytical services	USA	Direct	99.53%	0%
				Indirect	0.47%	100%
Ompi do Brasil I. e C. de Em. Far. Ltda	Biopharmaceutical	Production of drug containment systems	Brazil	Direct	79%	79%
				Indirect	21%	21%
Ompi Pharm. Packing Techn. Co. Ltd	Biopharmaceutical	Production of drug containment systems	China	Indirect	100%	100%
Innoscan A/S	Engineering	Production plant and machinery	Denmark	Indirect	100%	100%
SVM Automatik A/S	Engineering	Production plant and machinery	Denmark	Indirect	100%	100%
Medirio SA	Biopharmaceutical	Research and development	Switzerland	Indirect	100%	100%
Balda Medical GmbH	Biopharmaceutical	Production of in-vitro diagnostic solutions	Germany	Direct	100%	100%
Balda C. Brewer Inc.	Biopharmaceutical	Production of in-vitro diagnostic solutions	USA	Indirect	100%	100%
Balda Precision Inc.	Biopharmaceutical	Production metal components	USA	Indirect	100%	100%
Ompi of Japan Co., Ltd.	Biopharmaceutical	Sale of drug containment systems	Japan	Direct	51%	51%

#### Non-controlling interests

The non-controlling interests as of September 30, 2022 and the net profit attributable to non-controlling interests during the nine months ended September 30, 2022 relate to Ompi of Japan Co., Ltd. and Medical Glass a.s.

#### 5.Financial Risk Factors

The Group is exposed to the following financial risks connected with its operations:

- financial market risk, mainly related to foreign currency exchange rates and interest rates;

- liquidity risk, related to the availability of funds and access to the credit market, should the Group require it, and to financial instruments in general;
- credit risk, arising both from its normal commercial relations with customers, and its financing activities.

These risks could significantly affect the Group's financial position, results of operations and cash flows. Therefore, the Group identifies and monitors these risks to identify potential negative effects in advance and takes action to mitigate them, primarily through its operating and financing activities and if required, through the use of derivative financial instruments.

The interim condensed consolidated financial statements do not include all the information and notes on financial risk management required in the annual consolidated financial statements. For a detailed description of the financial risk factors and financial risk management of the Group, reference should be made to Note 40 of the Consolidated Financial Statements at and for the year ended December 31, 2021.

Although there are no significant negative impacts from the COVID-19 pandemic on the Group's exposure to financial risks or risk management procedures in the periods presented by these interim condensed consolidated financial statements, management is continuously monitoring the evolution of COVID-19 as information becomes available and the related effects on the financial position and results of operations of the Group. Please refer to Note 33 for further details.

Management is monitoring developments in the conflict between Russia and Ukraine and resulting financial and economic sanctions imposed by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia and Belarus. Primarily as a result of the Russian-Ukrainian conflict, gas and electricity prices have risen dramatically and affected Group margins, but the Group has not faced any material disruption in accessing natural gas for its operations to date. Please refer to Note 34 for further details.

### **Climate change**

Climate change and potential climate change legislation may present risks to the Group's operations, including business interruption, significantly increased costs and other adverse consequences to the Group's business. Some of the potential impacts of climate change to the business include physical risks to the Group's facilities, water and energy supply limitations or interruptions, disruptions to supply chain and impairment of other resources. In addition, if legislation or regulations are enacted or promulgated in the U.S., Europe or Asia or any other jurisdictions in which the Group does business that limit or reduce allowable greenhouse gas emissions and other emissions, such restrictions could have a significant effect on the Group's operating and financial decisions, including those involving capital expenditures to reduce emissions, and the results of operations. Manufacturing operations may not be able to operate as planned if the Group is not able to comply with new legal and regulatory legislation around climate change, or it may become too costly to operate in a profitable manner. Additionally, suppliers' added expenses could be passed on to the Group in the form of higher prices and the Group may not be able to pass on such expenses to its customers through price increases. With the impacts of climate change already manifesting themselves, and some degree of further global warming inevitable, the Group is keen to protect the environment, to operate business at global level under the principles of sustainability including principles related to climate-change and to include EHS management as an integral part of its business processes with the commitment to reduce energy and natural resources consumption. In preparing the Consolidated Financial Statements, management has considered the impact of climate change in the context of the disclosures. These considerations did not have a material impact on the financial reporting judgements and estimates and are consistent with the assessment that climate change is not expected to have a significant impact on the Group's going concern assessment to December 2022.

### **6.Foreign currency exchange**

The principal foreign currency exchange rates used to translate other currencies into Euro were as follows:

COUNTRY	ISO CODE	Average for nine months ended September 30, 2022	At September 30, 2022	Average for nine months ended September 30, 2021	At September 30, 2021
CHINA	CNY	7.0193	6.9368	7.7376	7.4847
UNITED STATES	USD	1.0638	0.9748	1.1962	1.1579
MEXICO	MXN	21.5542	19.6393	24.0772	23.7439
DENMARK	DKK	7.4399	7.4365	7.4368	7.4360
BRAZIL	BRL	5.4631	5.2584	6.3764	6.2631
SWITZERLAND	CHF	1.0118	0.9561	1.0904	1.0830
JAPAN	JPY	135.9679	141.0100	129.8320	129.6700

#### 7. Seasonality of operations

Historically, the Group's business operations have not experienced seasonality.

#### 8. Segment Information

The Group's business operations are organized into two reportable segments, based on their specific products and services:

- *Biopharmaceutical and Diagnostic Solutions*, which includes the products, processes and services developed and provided in connection with the containment and delivery of pharmaceutical and biotechnology drugs and reagents (such as vials, cartridges, syringes and drug delivery systems such as pen injectors, auto injectors and wearables), as well as the production of diagnostic consumables;

- *Engineering*, which includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes (assembly, visual inspection, packaging and serialization and glass converting).

For the nine months ended September 30, 2022, the Group generated 82% of total sales from the Biopharmaceutical and Diagnostic Solutions Segment (compared to 83% for the nine months ended September 30, 2021), and 18% from the Engineering Segment (compared to 17% for the nine months ended September 30, 2021).

The criteria applied to identify the operating segments are consistent with the information reviewed by the Chief Executive Officer (the Group's "Chief Operating Decision Maker") in making decisions regarding the allocation of resources and to assess performance.

As at and for the three months ended September 30, 2022					
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total segments	Adjustments, eliminations and unallocated items	Consolidated
(EUR thousand)					
External Customers	207,095	38,166	245,261	(0)	245,261
Inter-Segment	426	32,501	32,926	(32,926)	—
<b>Total Revenues</b>	<b>207,521</b>	<b>70,667</b>	<b>278,188</b>	<b>(32,926)</b>	<b>245,261</b>
Cost of Sales	139,722	55,418	195,140	(27,418)	167,722
<b>Gross Profit</b>	<b>67,799</b>	<b>15,249</b>	<b>83,047</b>	<b>(5,508)</b>	<b>77,539</b>
Other operating income	3,505	(4)	3,501	(54)	3,447
Selling and Marketing expenses	2,706	611	3,317	2,582	5,898
Research and Development expenses	5,401	1,879	7,280	334	7,614
General and Administrative expenses	15,895	2,831	18,727	1,192	19,919
<b>Operating Profit</b>	<b>47,302</b>	<b>9,923</b>	<b>57,224</b>	<b>(9,670)</b>	<b>47,554</b>
<b>Total assets</b>	<b>1,215,291</b>	<b>358,240</b>	<b>1,573,531</b>	<b>54,697</b>	<b>1,628,230</b>
<b>Total liabilities</b>	<b>510,940</b>	<b>252,028</b>	<b>762,968</b>	<b>(97,851)</b>	<b>665,116</b>

As at and for the three months ended September 30, 2021					
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total segments	Adjustments, eliminations and unallocated items	Consolidated
(EUR thousand)					
External Customers	172,757	41,778	214,535	—	214,535
Inter-Segment	330	17,678	18,009	(18,009)	—
<b>Total Revenues</b>	<b>173,087</b>	<b>59,456</b>	<b>232,543</b>	<b>(18,009)</b>	<b>214,535</b>
Cost of Sales	119,159	50,304	169,463	(18,200)	151,262
<b>Gross Profit</b>	<b>53,928</b>	<b>9,152</b>	<b>63,081</b>	<b>192</b>	<b>63,273</b>
Other operating income	1,725	—	1,725	—	1,725
Selling and Marketing expenses	1,860	500	2,360	2,347	4,707
Research and Development expenses	5,790	988	6,778	615	7,393
General and Administrative expenses	16,683	3,440	20,123	4,542	24,665
<b>Operating Profit</b>	<b>31,320</b>	<b>4,224</b>	<b>35,544</b>	<b>(7,312)</b>	<b>28,233</b>
<b>Total assets</b>	<b>839,863</b>	<b>215,667</b>	<b>1,055,530</b>	<b>331,330</b>	<b>1,386,860</b>
<b>Total liabilities</b>	<b>327,091</b>	<b>132,908</b>	<b>459,999</b>	<b>135,368</b>	<b>595,368</b>



As at and for the nine months ended September 30, 2022					
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total segments	Adjustments, eliminations and unallocated items	Consolidated
(EUR thousand)					
External Customers	568,138	123,444	691,582	(0)	691,582
Inter-Segment	1,009	83,696	84,704	(84,704)	—
<b>Total Revenues</b>	<b>569,147</b>	<b>207,139</b>	<b>776,286</b>	<b>(84,704)</b>	<b>691,582</b>
Cost of Sales	380,948	162,089	543,037	(71,014)	472,022
<b>Gross Profit</b>	<b>188,199</b>	<b>45,051</b>	<b>233,250</b>	<b>(13,690)</b>	<b>219,560</b>
Other operating income	12,229	(6)	12,223	(97)	12,126
Selling and Marketing expenses	8,619	1,871	10,490	7,331	17,821
Research and Development expenses	17,785	4,609	22,394	1,403	23,797
General and Administrative expenses	46,453	8,574	55,027	5,731	60,758
<b>Operating Profit</b>	<b>127,571</b>	<b>29,990</b>	<b>157,561</b>	<b>(28,252)</b>	<b>129,309</b>
<b>Total assets</b>	<b>1,215,291</b>	<b>358,240</b>	<b>1,573,531</b>	<b>54,697</b>	<b>1,628,230</b>
<b>Total liabilities</b>	<b>510,940</b>	<b>252,028</b>	<b>762,968</b>	<b>(97,851)</b>	<b>665,116</b>

As at and for the nine months ended September 30, 2021					
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total segments	Adjustments, eliminations and unallocated items	Consolidated
(EUR thousand)					
External Customers	508,175	103,172	611,348	—	611,348
Inter-Segment	789	39,278	40,067	(40,067)	—
<b>Total Revenues</b>	<b>508,964</b>	<b>142,450</b>	<b>651,414</b>	<b>(40,067)</b>	<b>611,348</b>
Cost of Sales	340,196	116,809	457,005	(38,028)	418,976
<b>Gross Profit</b>	<b>168,768</b>	<b>25,641</b>	<b>194,409</b>	<b>(2,038)</b>	<b>192,372</b>
Other operating income	7,206	—	7,206	—	7,206
Selling and Marketing expenses	7,107	2,251	9,357	6,642	15,999
Research and Development expenses	15,889	2,985	18,874	1,236	20,110
General and Administrative expenses	41,786	8,383	50,169	(5,467)	44,702
<b>Operating Profit</b>	<b>111,192</b>	<b>12,023</b>	<b>123,215</b>	<b>(4,449)</b>	<b>118,767</b>
<b>Total assets</b>	<b>839,863</b>	<b>215,667</b>	<b>1,055,530</b>	<b>331,330</b>	<b>1,386,860</b>
<b>Total liabilities</b>	<b>327,091</b>	<b>132,908</b>	<b>459,999</b>	<b>135,368</b>	<b>595,368</b>

Inter-segment revenue and costs are eliminated upon consolidation and reflected in the “adjustments, elimination and unallocated items” column. The most relevant adjustment in revenue relates to the sales of the equipment manufactured by the Engineering Segment for use by the Biopharmaceutical and Diagnostic Solutions Segment.

The reconciliation from total segments Operating Profit to consolidated Profit Before Tax is as follows:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
	(EUR thousand)		(EUR thousand)	
<b>Segments Operating Profit</b>	<b>57,224</b>	<b>35,544</b>	<b>157,561</b>	<b>123,215</b>
Finance income	6,736	2,066	17,235	6,381
Finance expense	8,250	8,032	22,734	13,681
Share of profit of an associate	—	150	—	547
Inter-segment elimination	(9,670)	(7,312)	(28,252)	(4,449)
<b>Profit Before Tax</b>	<b>46,040</b>	<b>22,417</b>	<b>123,810</b>	<b>112,014</b>

As of September 30, 2022, the Biopharmaceutical and Diagnostic Solutions Segment and the Engineering Segment had one and two customers, respectively, that individually represented more than 10% of segment's revenue.

As of September 30, 2021, the Biopharmaceutical and Diagnostic Solutions Segment and the Engineering Segment had two and three customers, respectively, that individually represented more than 10% of segment's revenue.

For the nine months ended September 30, 2022, revenue generated by the Biopharmaceutical and Diagnostic Solutions Segment increased by EUR 60,183 thousand, or 11.8%, to EUR 569,147 thousand, compared to EUR 508,964 thousand for the nine months ended September 30, 2021. All growth was organic and driven by increased revenue from premium priced, high-value solutions and the positive effect of forex of EUR 19,818 thousand or 3.6%. Revenue for the nine months ended September 30, 2021, included a EUR 5.5 million benefit from a licensing agreement. Excluding this benefit, revenue from the Biopharmaceutical and Diagnostic Solutions Segment would have increased by 13.0% in that period.

For the nine months ended September 30, 2022, Engineering Segment revenue increased by EUR 64,689 thousand, or 45.4%, to EUR 207,139 thousand, compared to EUR 142,450 thousand for the nine months ended September 30, 2021, primarily as a result of a steep increase in inter-segment revenue and solid growth from external customers across all business lines including aftersales.

Inter-segment revenue generated by the Engineering Segment for equipment used in our Biopharmaceutical and Diagnostic Solutions Segment increased by EUR 44,418 thousand, or 113.1%, to EUR 83,696 thousand for the nine months ended September 30, 2022, compared to EUR 39,278 thousand for the nine months ended September 30, 2021. The increase in Inter-segment Engineering revenue resulted from the sale of production equipment to support the Group's strategic investment initiatives in capacity expansion predominantly in its high-value solutions products to satisfy increasing customer demand.

## 9. Revenue from contracts with customers

### Disaggregated revenue information

The table below shows the disaggregation of the Group's revenue from contracts with external customers:

	For the three months ended September 30, 2022		
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total
	(EUR thousand)		
<b>Type of goods or service</b>			
Revenues from high-value solutions	74,418	—	74,418
Revenues from other containment and delivery solutions	132,677	—	132,677
Revenues from engineering	—	38,166	38,166
<b>Total revenue from contracts with customers</b>	<b>207,095</b>	<b>38,166</b>	<b>245,261</b>
<b>Geographical markets</b>			
EMEA	134,013	18,738	152,751
APAC	20,294	2,547	22,840
North America	44,086	16,076	60,162
South America	8,702	806	9,508
<b>Total revenue from contracts with customers</b>	<b>207,095</b>	<b>38,166</b>	<b>245,261</b>
<b>Timing of revenue recognition</b>			
Goods and services transferred at a point in time	201,889	4,115	206,004
Goods and services transferred over time	5,206	34,051	39,257
<b>Total revenue from contracts with customers</b>	<b>207,095</b>	<b>38,166</b>	<b>245,261</b>

	For the three months ended September 30, 2021		
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total
	(EUR thousand)		
<b>Type of goods or service</b>			
Revenues from high-value solutions	48,382	—	48,382
Revenues from other containment and delivery solutions	124,375	—	124,375
Revenues from engineering	—	41,778	41,778
<b>Total revenue from contracts with customers</b>	<b>172,757</b>	<b>41,778</b>	<b>214,535</b>
<b>Geographical markets</b>			
EMEA	105,157	22,008	127,165
APAC	20,010	13,184	33,194
North America	40,998	5,856	46,854
South America	6,592	730	7,322
<b>Total revenue from contracts with customers</b>	<b>172,757</b>	<b>41,778</b>	<b>214,535</b>
<b>Timing of revenue recognition</b>			
Goods and services transferred at a point in time	167,814	7,688	175,502
Goods and services transferred over time	4,943	34,090	39,033
<b>Total revenue from contracts with customers</b>	<b>172,757</b>	<b>41,778</b>	<b>214,535</b>

	For the nine months ended September 30, 2022		
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total
	(EUR thousand)		
<b>Type of goods or service</b>			
Revenues from high-value solutions	206,013	—	206,013
Revenues from other containment and delivery solutions	362,125	—	362,125
Revenues from engineering	—	123,444	123,444
<b>Total revenue from contracts with customers</b>	<b>568,138</b>	<b>123,444</b>	<b>691,582</b>
<b>Geographical markets</b>			
EMEA	352,639	61,335	413,974
APAC	52,721	21,544	74,265
North America	141,146	37,600	178,746
South America	21,632	2,965	24,597
<b>Total revenue from contracts with customers</b>	<b>568,138</b>	<b>123,444</b>	<b>691,582</b>
<b>Timing of revenue recognition</b>			
Goods and services transferred at a point in time	554,368	12,915	567,283
Goods and services transferred over time	13,770	110,529	124,299
<b>Total revenue from contracts with customers</b>	<b>568,138</b>	<b>123,444</b>	<b>691,582</b>

	For the nine months ended September 30, 2021		
	Biopharmaceutical and Diagnostic Solutions	Engineering	Total
	(EUR thousand)		
<b>Type of goods or service</b>			
Revenues from high-value solutions	141,426	—	141,426
Revenues from other containment and delivery solutions	366,749	—	366,749
Revenues from engineering	—	103,172	103,172
<b>Total revenue from contracts with customers</b>	<b>508,175</b>	<b>103,172</b>	<b>611,348</b>
<b>Geographical markets</b>			
EMEA	308,167	54,942	363,109
APAC	52,771	24,526	77,297
North America	129,608	22,732	152,340
South America	17,629	972	18,601
<b>Total revenue from contracts with customers</b>	<b>508,175</b>	<b>103,172</b>	<b>611,348</b>
<b>Timing of revenue recognition</b>			
Goods and services transferred at a point in time	491,383	31,718	523,102
Goods and services transferred over time	16,792	71,454	88,246
<b>Total revenue from contracts with customers</b>	<b>508,175</b>	<b>103,172</b>	<b>611,348</b>

The Group's revenue is divided into two main segments:

- Biopharmaceutical and Diagnostic Solutions: this segment includes all the products and services developed and provided for containment and delivery of bio-pharmaceutical drugs and diagnostic reagents (such as vials, cartridges, syringes and drug delivery systems like pen injectors, auto injectors and wearables). This segment is further divided into two sub-categories:

- High-value solutions: wholly owned, internally developed products, processes and services for which the Group holds intellectual property rights or has strong proprietary know-how and are characterized by higher complexity or superior performance;

•Other containment and delivery solutions.

•Engineering: this segment includes all the equipment and technologies developed and provided to support the end-to-end bio-pharmaceutical and diagnostic manufacturing processes.

Consolidated revenue at current exchange rates increased by EUR 80,234 thousand, or 13.1%, to EUR 691,582 thousand for the nine months ended September 30, 2022, compared to EUR 611,348 thousand for the nine months ended September 30, 2021. Consolidated revenue at constant currency (i.e., excluding the impact of fluctuations in currency exchange rates) increased by 9.9% for the nine months ended September 30, 2022. Year-over-year revenue growth was driven by growth in both Segments.

In the Biopharmaceutical and Diagnostic Solution Segment, revenue from high-value solutions increased by EUR 64,587 thousand, or 45.7%, to EUR 206,013 thousand for the nine months ended September 30, 2022 compared to EUR 141,426 thousand for the nine months ended September 30, 2021, while revenue from other containment and delivery solutions decreased by EUR 4,624 thousand, or 1.3%, to EUR 362,125 thousand for the nine months ended September 30, 2022 compared to EUR 366,749 thousand for the nine months ended September 30, 2021. Revenue in the Biopharmaceutical and Diagnostic Solutions Segment increased by 14.4% in EMEA, 8.9% in North America, and 22.7% in South America, and decreased by 0.1% in APAC. Revenue in the Engineering Segment increased by 11.6% in EMEA, 65.4% in North America, and 205.1% in South America, and decreased by 12.2% in APAC.

Within the Engineering Segment, revenue from contracts with external customers increased by EUR 20,272 thousand, or 19.6%, to EUR 123,444 thousand for the nine months ended September 30, 2022, compared to EUR 103,172 thousand for the nine months ended September 30, 2021, driven by higher sales to external customers across all business lines, visual inspection systems, assembly and packaging machines, glass converting machines, and also aftersales activities. Revenue recognized over time increased by EUR 39,075 thousand, or 54.7%, to EUR 110,529 thousand for the nine months ended September 30, 2022, from EUR 71,454 thousand for the nine months ended September 30, 2021, driven by new contracts and continued progress on orders where the Group has an enforceable right to payment for the performance completed to date.

#### Contract balances

The following table provides information on contractual asset from contracts with customer:

	At September 30, 2022	At December 31, 2021
	(EUR thousand)	
Trade receivables	204,197	165,259
Contract assets	91,711	62,133
Contract liabilities	(23,111 )	(18,771 )
Advances from customers	(26,793 )	(23,616 )
<b>Total</b>	<b>246,004</b>	<b>185,005</b>

Contract assets mainly relate to the Group's right to consideration for performance of construction contracts to which the Group is a party and for which the Group has not yet issued an invoice as of the balance sheet date. The amount recognized as contract assets are reclassified to trade receivables as soon as the Group has an unconditional right to consideration.

#### 10. Cost of sales

Cost of sales are detailed as follows:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
	(EUR thousand)		(EUR thousand)	
Purchases	107,400	79,918	272,930	199,309
Change in inventories	(26,593)	4,528	(48,422)	15,726
Direct industrial labour	33,421	28,030	96,015	85,446
Indirect industrial labour	14,767	12,454	44,086	36,982
Industrial depreciation and amortization	13,803	12,330	39,519	33,889
Other costs of sales	24,924	14,002	67,894	47,624
<b>Total Cost of sales</b>	<b>167,722</b>	<b>151,262</b>	<b>472,022</b>	<b>418,976</b>

Cost of sales increased for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021, mainly due to the higher cost of materials, components and labor expenses related to the production and distribution of our goods and services. Cost of sales was also impacted by an increase in logistical costs and utilities, mainly due to the worldwide increase in natural gas and electricity rates. Industrial depreciation and amortization increased due to the availability for use of the machinery installed in the previous months to increase the production capacity.

For the nine months ended September 30, 2022, cost of sales included €1.9 million of non-recurring start-up costs related to the new facilities in Indiana, U.S., in Zhangjiagang, China, and in Latina, Italy

## 11. Other operating income

Other operating income for the nine months ended September 30, 2022, and 2021, amounts to EUR 12,126 thousand and EUR 7,206 thousand, respectively, relating mainly to: (i) contributions from customers for pre-feasibility and feasibility studies, development and customization of the Group's proprietary products; (ii) design and sample activities to perform and improve feasibility studies on customized containment solutions; (iii) development and validation activities such as closure validation relating to the last project milestones that allow products industrialization; (iv) post development and validation analysis performed on containment and drug delivery solutions to assure safety and quality; (v) manual samples preparation and packaging; (vi) contract modification fees; and (vii) other recharges.

In the third quarter of 2022, other income included approximately €1.6 million related to contract modifications and includes residual fees related to a contract modification disclosed in the second quarter of 2022 which was made to accommodate a decrease in COVID-19 related orders.

## 12. Expenses

Expenses are detailed as follows:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
	(EUR thousand)		(EUR thousand)	
Selling and Marketing expenses	5,898	4,707	17,821	15,999
Research and Development expenses	7,614	7,393	23,797	20,110
General and Administrative expenses	19,919	24,665	60,758	44,702
<b>Total Expenses</b>	<b>33,431</b>	<b>36,765</b>	<b>102,376</b>	<b>80,811</b>

For the nine months ended September 30, 2022, Selling and Marketing expenses were EUR 17,821 thousand compared to EUR 15,999 thousand for the nine months ended September 30, 2021. These expenses are mainly related to personnel expenses for the sales organizations. They include depreciation for EUR 522 thousand compared to EUR 586 thousand for the nine months ended September 30, 2021 and the release of a provision for bad and doubtful debts for EUR 141 thousand compared to an accrual of EUR 720 thousand for the nine months ended September 30, 2021. Selling and Marketing expenses increased mainly due to higher costs for business development and industry events, strategic marketing and travel costs.

The changes reflect business development activities returning to pre-pandemic levels offset by lower accruals for bad and doubtful debts following the improvement of some positions with external customers.

Research and Development expenses for the nine months ended September 30, 2022, amounted to EUR 23,797 thousand compared to EUR 20,110 thousand for the nine months ended September 30, 2021 and include costs for research and development activities to support product innovation, and amortization and depreciation for EUR 2,589 thousand, compared to EUR 2,462 thousand for the nine months ended September 30, 2021. The increase in Research and Development expenses reflected the Group efforts in driving constant innovation in premium primary packaging and drug delivery systems to maintain and build on its market-leading position, strengthen the IP, and develop new technologies to advance patient care.

General and Administrative expenses increased to EUR 60,758 thousand for the nine months ended September 30, 2022, from EUR 44,702 thousand for the nine months ended September 30, 2021. The increase was mainly due to higher labor costs for the nine months ended September 30, 2022, compared to the nine months ended September 30, 2021, which benefitted from the reversal of an accrual of EUR 9,884 thousand in connection with the termination of the incentive plans 2012-2021 and 2018-2022 which were replaced by the new stock grant plan 2021-2027. The effects of the reversal of the accrual for the nine months ended September 30, 2021 were partially offset by a EUR 6,696 thousand discretionary, out-of-cycle bonus to personnel. In addition, General and Administrative expenses increased due to non-recurring, start-up costs for the new EZ-fill® hub in Fishers, Indiana, United States of EUR 2,589 thousand. Finally, the increase in costs associated with the status of being listed on the NYSE, such as insurance and other organizational costs, as well as higher IT costs, unfavorably impacted General and Administrative expenses for the nine months ended September 30, 2022.

### 13. Finance income

Finance income is as follows:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
	(EUR thousand)		(EUR thousand)	
Interest income from banks deposits	142	138	462	410
Income from financial discounts	(42)	3	7	15
Interest income on loan to associates	—	—	—	10
Other financial income	9	1	17	31
Foreign currency exchange rate gains	6,369	1,811	15,466	4,830
Derivatives revaluation	257	(223)	1,056	749
Other fair value adjustments	1	336	227	337
<b>Total finance income</b>	<b>6,736</b>	<b>2,066</b>	<b>17,235</b>	<b>6,381</b>

### 14. Finance expense

Finance expenses are as follows:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
	(EUR thousand)		(EUR thousand)	
Interest on debts and borrowings	807	849	2,427	3,092
Financial discounts and other expenses	(158)	35	28	43
Interest on lease liabilities	147	144	431	441
Financial component IAS 19	29	5	86	25
Foreign currency exchange losses	2,754	5,241	9,509	7,754
Derivatives devaluation	4,662	1,463	10,015	1,901
Other fair value adjustments	9	294	238	424
<b>Total finance expense</b>	<b>8,250</b>	<b>8,032</b>	<b>22,734</b>	<b>13,681</b>

Finance expenses include bank interest on the Group's financial debt (recalculated using the amortized cost method) and interest on leases related to the portion of financial expenses payable matured in the reporting period on the liabilities, recognized in accordance with IFRS 16 - Leases.

Foreign exchange differences are realized and unrealized gains and losses incurred on transactions in currencies other than the functional currency of the Group; the net foreign currency exchange impact, given by the sum of gains and losses, amounts to a net gain of EUR 5,957 thousand for the nine months ended September 30, 2022, and a net loss of EUR 2,924 thousand for the nine months ended September 30, 2021.

The progressive weakening of the euro during the first nine months of 2022 against the foreign currencies to which the Group is mainly exposed to (i.e., USD and CNY), impacted both foreign currency exchange rate and derivative devaluation.

### 15. Income tax

Income tax expense amounted to EUR 29,135 thousand for the nine months ended September 30, 2022, compared to EUR 22,347 thousand for the nine months ended September 30, 2021.

The effective tax rate for the nine months ended September 30, 2022, was 23.5% compared to 19.95% for the nine months ended September 30, 2021. The effective tax rate for the nine months ended September 30, 2021, was positively affected by a retroactive EUR 5.5 million tax saving for the financial years 2016-2020 that was recognized in the first quarter of 2021 and additional EUR 1.6 million accounted for the three months ended September 30, 2021 related to the so called "Patent Box regime", which was a tax exemption for the use of intellectual property assets. This was partially offset by the reversal of deferred tax assets amounting to €4.8 million following the early termination of incentive plans 2012-2021 and 2018-2022 which were terminated in favor of the new stock grant plan 2021-2027. The normalized effective tax rate without this one-off item was 24.38%.

### 16. Earnings per Share

Basic earnings per share (EPS) is calculated by dividing the profit attributable to equity holders of the parent by the weighted average number of common shares issued, net of the treasury shares, held by the Group.

There is no significant dilution impact for the three and nine months ended September 30, 2022, resulting in basic and diluted earnings per share being the same for the three and the nine months ended September 30, 2021. The weighted average number of shares for purposes of calculating diluted earnings per share increased to take into consideration the theoretical effect of potential ordinary shares that could be assigned to the beneficiaries based on the Group's equity incentive plans (see [Note 27](#) for further details on the equity incentive plans).

The Shareholder's meeting held on July 1, 2021 approved a share split and all the existing 100,010,000 shares were split into a total of 272,427,240 shares in the ratio of 2,724 new shares post-split for each share outstanding prior to the share split.



The number of ordinary shares outstanding has been retrospectively adjusted as if such event had occurred at the beginning of the earliest period presented. The following table reflects the income and shares data used in the basic and diluted EPS calculation:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022 (EUR thousand)	2021	2022 (EUR thousand)	2021
Profit attributable to ordinary equity holders of the parent	36,215	18,655	94,469	89,647
Weighted average number of ordinary shares for basic EPS	264,699,481	264,461,882	264,699,481	248,661,336
Weighted average number of ordinary shares adjusted for the effect of dilution	264,701,370	264,488,975	264,701,370	248,676,387
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Basic earnings per common share (in EUR)	0.14	0.07	0.36	0.36
Diluted earnings per common share (in EUR)	0.14	0.07	0.36	0.36

## 17. Intangible assets

Changes in intangible assets as of September 30, 2022, are as follows:

	Total (EUR thousand)
<b>Cost</b>	
At January 1, 2021	69,883
Additions	5,489
Disposals	(1,744 )
Exchange differences	632
At December 31, 2021	74,260
Additions	7,799
Exchange differences	1,158
At September 30, 2022	<u>83,217</u>
<b>Amortization</b>	
At January 1, 2021	35,982
Amortization	7,504
Disposal	(1,335 )
Exchange differences	181
At December 31, 2021	42,332
Amortization	5,993
Exchange differences	448
At September 30, 2022	<u>48,773</u>
<b>Net book value</b>	
At September 30, 2022	34,446
At December 31, 2021	31,928

Additions in intangible assets amounting to EUR 7,799 thousand for the nine months ended September 30, 2022, are related to the capitalization of costs associated with an upgrade of the Group's ERP software and other software licenses. No impairment indicators were identified during the nine months period ended September 30, 2022.

## 18. Property, plant and equipment

Changes in items of property, plant and equipment as of September 30, 2022 are as follows:

	<b>Total</b> <b>(EUR thousand)</b>
<b>Cost</b>	
<b>At January 1, 2021</b>	<b>638,031</b>
Additions	116,631
Disposals	(9,544 )
Exchange differences	9,642
<b>At December 31, 2021</b>	<b>754,760</b>
Additions	194,605
Disposals	(2,620 )
Exchange differences	29,851
<b>At September 30, 2022</b>	<b>976,596</b>
<b>Depreciation and impairment</b>	
<b>At January 1, 2021</b>	<b>324,374</b>
Depreciation charge for the year	41,734
Impairment	943
Disposals	(8,933 )
Exchange differences	3,925
<b>At December 31, 2021</b>	<b>362,043</b>
Depreciation charge for the period	36,993
Impairment	43
Disposals	(2,298 )
Exchange differences	9,636
<b>At September 30, 2022</b>	<b>406,417</b>
<b>Net book value</b>	
At September 30, 2022	570,178
At December 31, 2021	392,717

For the nine months ended September 30, 2022, additions (property, plant and equipment increase of EUR 194,605 thousand) are mainly due to the advancement of construction for the Group's new facilities in the U.S. and China, expansion of the Group's headquarters and production facilities in Piombino Dese and the acquisition of a brownfield plant in Latina (Italy). Additions also include investments for new manufacturing equipment for the production of EZ-Fill® and bulk syringes, vials and cartridges as the Group continues the build out of its global capacity expansion initiatives.

#### 19.Right of Use

The Group has lease contracts for various items of plant, machinery, vehicles and other equipment used in its operations. Leases of plant and machinery generally have lease terms between 3 and 15 years, while vehicles and other equipment generally have lease terms between 3 and 5 years. There are several lease contracts that include extension and termination options.

The Group also has certain leases with lease terms of 12 months or less and leases of office equipment with low value. The Group applies the 'short-term lease' and 'lease of low-value assets' recognition exemptions for these leases.

Movements in the leased Right of Use assets for the first nine months of 2022 are shown below:

	<b>Total (EUR thousand)</b>
<b>Cost</b>	
<b>At January 1, 2021</b>	<b>35,992</b>
Additions	3,111
Disposals	(1,655 )
Exchange differences	960
<b>At December 31, 2021</b>	<b>38,408</b>
Additions	2,254
Disposals	(628 )
Exchange differences	1,801
<b>At September 30, 2022</b>	<b>41,835</b>
<b>Depreciation</b>	
<b>At January 1, 2021</b>	<b>10,612</b>
Depreciation charge for the year	6,202
Disposals	(1,337 )
Exchange differences	241
<b>At December 31, 2021</b>	<b>15,718</b>
Depreciation charge for the period	4,724
Disposals	(150 )
Exchange differences	508
<b>At September 30, 2022</b>	<b>20,800</b>
<b>Net book value</b>	
At September 30, 2022	21,035
At December 31, 2021	22,690

## 20. Financial assets

The following table details the composition of financial assets:

	<b>At September 30, 2022</b>	<b>At December 31, 2021</b>
	<b>(EUR thousand)</b>	
Receivables from financing activities	—	447
Other non-current financial assets	913	887
<b>Other non-current financial assets</b>	<b>913</b>	<b>1,334</b>
Fair value of derivatives financial instruments	6,026	49
Other securities	27,393	27,168
<b>Other current financial assets</b>	<b>33,419</b>	<b>27,217</b>
<b>Financial assets</b>	<b>34,332</b>	<b>28,551</b>

As of December 31, 2021, receivables from financing activities included a financial loan of EUR 447 thousand for a limited number of key managers related to the restricted stock grant plan 2021-2027. This loan was fully reimbursed in May 2022.

Other securities include guaranteed investment funds managed by Société Générale SA, which are measured at fair value. The increase in other securities is due to the revaluation of their fair value.

## 21. Inventories

Inventories, shown net of an allowance for obsolete and slow-moving goods, can be analyzed as follows:

	At September 30, 2022	At December 31, 2021
	(EUR thousand)	
Raw materials	77,657	58,484
Semifinished products	33,383	29,878
Finished products	100,382	64,252
Advances to suppliers	20,291	9,554
Provision from slow moving and obsolescence	(13,661 )	(13,251 )
<b>Total inventories</b>	<b>218,052</b>	<b>148,917</b>

The provision for slow moving and obsolete inventories as of September 30, 2022, and December 31, 2021, amounted to EUR 13,661 thousand and EUR 13,251 thousand, respectively, with an accrual of EUR 576 thousand recognized within cost of sales and other changes due to exchange rate movements for EUR (165) thousand for the nine months ended September 30, 2022. The significant increase in Total Inventories was driven by organic growth in our business and supply chain risk mitigation.

## 22. Trade receivables and contract assets

Trade receivables and contract assets are analyzed as follows:

	At September 30, 2022	At December 31, 2021
	(EUR thousand)	
Trade receivables	210,938	171,803
Allowance for expected credit losses	(6,742 )	(6,544 )
<b>Total trade receivables</b>	<b>204,197</b>	<b>165,259</b>
<i>Expected credit loss rate</i>	3.2 %	3.8 %

Trade receivables are non-interest bearing and generally have a term of 60 to 90 days. The Group is not exposed to significant concentration of third-party credit risk. Trade receivables are stated net of an allowance for expected credit losses which has been determined in accordance with IFRS 9 amounting to EUR 6,742 thousand and EUR 6,544 thousand as of September 30, 2022, and December 31, 2021, respectively.

## Contract assets

Contract assets relate to revenue earned from ongoing customer-specific construction contracts within the Engineering Segment and from the In-vitro diagnostic business, which is part of the Biopharmaceutical and Diagnostic Solutions Segment. As such, the balances of this account vary and are dependent on the number of ongoing construction contracts at the end of the period. The Group had contract assets of EUR 91,711 thousand as of September 30, 2022, and EUR 62,133 thousand as of December 31, 2021. Contract assets gross amounts to EUR 212,902 thousand (EUR 138,854 thousand as of December 31, 2021), net of invoices issued of EUR 121,190 thousand (EUR 76,721 thousand as of December 31, 2021).

## 23. Tax receivables and tax payables

As of September 30, 2022, tax receivables amounted to EUR 34,787 thousand compared to EUR 25,063 thousand as of December 31, 2021, and tax liabilities amounted to EUR 43,073 thousand compared to EUR 19,440 thousand as of December 31, 2021. The total net balance as of September 30, 2022, is a payable amounting to EUR 8,286 thousand, while the net balance as of December 31, 2021, was a receivable amounting to EUR 5,623 thousand.

The change in net balance is mainly due to the increased payable for corporate income taxes accrued for the nine months ended September 30, 2022, against lower mandatory tax advances paid in the same period and due to the fact that Italian subsidiaries of the Group settled the Corporate Income Taxes balance related to fiscal year 2021 in the month of August.

## **24. Equity**

The main objective of the Group's capital management is to maintain a solid credit rating and adequate financial ratios to support business activity and maximize value for shareholders.

Movements in the equity accounts are reported in the Interim Consolidated Statements of Changes in Equity; comments on the main components and their changes are provided below.

### **Share capital**

As of September 30, 2022, and as of December 31, 2021, the Company paid-in share capital amounted to EUR 21,698 thousand divided into 295,540,036 shares without par value, including 34,103,005 ordinary shares and 261,437,031 Class A multiple voting shares.

### **Share Premium Reserve**

The share premium reserve includes the additional paid-in capital raised during the Initial Public Offering, completed on July 15, 2022, net of the listing costs pertaining to the public subscription offer to the extent they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided. As of September 30, 2022, and as of December 31, 2021, the share premium reserve amounted to EUR 389,312 thousand.

### **Treasury Reserve**

As of September 30, 2022, and as of December 31, 2021, a total of 30,840,555 of the Company's Class A shares were held in treasury for a total cost of EUR (27,740) thousand.

### **Cash Flow Hedge Reserve**

Cash flow hedge reserve reflects the negative change in the fair value of derivatives financial instruments, designed as cash flow hedges to hedge highly probable forecast transactions. As of September 30, 2022, the cash flow hedge reserve was EUR 4,060 thousand compared to EUR (1,277) thousand as of December 31, 2021.

### **Currency translation reserve**

The currency translation reserve includes the cumulative foreign currency translation differences arisen from the translation of financial statements denominated in currencies other than Euro; as of September 30, 2022, it was EUR 4,061 thousand compared to EUR (22,680) thousand as of December 31, 2021. As of September 30, 2021, it amounted to EUR 27,384 thousand compared to EUR (34,911) thousand as of December 31, 2020. The decrease in the currency translation reserve is mainly due to the appreciation against the Euro of the Brazilian Real, the Mexican Peso, the Chinese Renminbi and the US Dollar which occurred in the last twelve months. These are the primary currencies in which the net assets of the Group's companies are denominated.

### **Retained Earnings and Other Reserves**

On June 1, 2022, Stevanato Group shareholders approved the distribution of EUR 13,500 thousand in dividends (EUR 0.051 per common share) in part from the net profits realized in the previous financial year and in part from "other reserves".

On January 20, 2021, Stevanato Group shareholders approved the distribution of EUR 11,200 thousand in dividends (EUR 0.63 thousand per common share) from “other reserves”. The dividend was paid on July 13, 2022 to shareholders of record as of June 14, 2022.

## 25. Financial liabilities

Total financial liabilities are EUR 243,728 thousand and EUR 248,491 thousand as of September 30, 2022, and as of December 31, 2021, respectively; the balances in financial debt are as follows:

	At September 30, 2022	At December 31, 2021
	(EUR thousand)	
Lease liabilities - Right of Use	5,642	5,553
Bank overdrafts	12,436	37
Bank loans	47,297	36,195
Financial liabilities due to related parties	869	940
Fair value of derivatives	5,872	1,681
Financial liabilities due to other lenders	796	1,789
<b>Total current financial liabilities</b>	<b>72,911</b>	<b>46,195</b>
Lease liabilities - Right of Use	16,101	17,574
Bank loans	105,050	134,367
Notes	49,666	49,620
Financial liabilities due to other lenders	—	735
<b>Total non-current financial liabilities</b>	<b>170,817</b>	<b>202,296</b>
<b>Financial liabilities</b>	<b>243,728</b>	<b>248,491</b>

Financial liabilities mainly include bank loans (current and non-current portions), lease liabilities (current and non-current portions) and notes.

Other current financial assets and other financial liabilities relate to foreign exchange derivatives. The following table sets forth the analysis of derivative assets and liabilities as of September 30, 2022, and December 31, 2021.

	At September 30, 2022		At December 31, 2021	
	Carrying amount	Fair value	Carrying amount	Fair value
	(EUR thousand)			
<b>Financial assets</b>				
Foreign exchange forward contracts	685	685	49	49
Interest Rate Swap in cash flow hedges	5,341	5,341	—	—
<b>Financial liabilities</b>				
Foreign exchange forward contracts	5,872	5,872	—	—
Interest Rate Swap in cash flow hedges	—	—	1,681	1,681

Derivatives on currency risk have not been designated as hedging instruments and reflect the change in the fair value of those foreign exchange forward contracts that are not designated in hedge relationships, but are, nevertheless, intended to reduce the level of foreign currency risk for expected sales.

Derivatives designated as hedging instruments reflect the change in fair value of the interest rate swap contracts, designated as cash flow hedges to hedge fluctuations in variable interest rate on loans. The amount recorded in the cash flow hedge reserve will be recognized in the consolidated income statement according to the timing of the cash flows of the underlying transaction.

## 26. Fair Value Measurement

IFRS 13 establishes a three-level hierarchy that categorizes the inputs to the valuation techniques used to measure fair value by giving the highest priority to quoted prices (unadjusted) in active markets for identical assets and liabilities (level 1 inputs) and the lowest priority to unobservable inputs (level 3 inputs).

In some cases, the inputs used to measure the fair value of an asset or a liability might be categorized within different levels of the fair value hierarchy. In those cases, the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy at the lowest level input that is significant to the entire measurement.

Levels used in the hierarchy are as follows:

- Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the group is the current bid price. These instruments are included in level 1.
- Level 2: The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximize the use of observable market data and rely, in part, on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.
- Level 3: If one or more of the significant inputs is not based on observable market data, the instruments are included in level 3. This is the case for unlisted equity securities.

### Assets and liabilities that are measured at fair value on a recurring basis

The following table shows the fair value hierarchy for financial assets and liabilities that are measured at fair value on a recurring basis at September 30, 2022, and at December 31, 2021:

As at September 30, 2022:

	Notes	Total	Fair value measurement using		
			Level 1	Level 2	Level 3
			(EUR thousand)		
Cash and cash equivalents		259,929	259,929	—	—
Financial assets - investments FVTPL - traded		786	786	—	—
Financial assets - investments FVTPL - not traded		309	—	—	309
Derivatives financial assets	20	6,026	—	6,026	—
Financial current assets	20	27,393	—	27,393	—
Other non-current financial assets		672	—	672	—
<b>Total assets</b>		<b>295,115</b>	<b>260,715</b>	<b>34,091</b>	<b>309</b>
Derivatives financial liabilities	25	5,872	—	5,872	—
<b>Total Liabilities</b>		<b>5,872</b>	<b>—</b>	<b>5,872</b>	<b>—</b>

As at December 31, 2021:

	Notes	Total	Fair value measurement using		
			Level 1	Level 2	Level 3
			(EUR thousand)		
Cash and cash equivalents		411,039	411,039	—	—
Financial assets - investments FVTPL		1,084	—	—	1,084
Derivatives financial assets	20	49	—	49	—
Financial current assets	20	27,168	—	27,168	—
Other non-current financial assets		671	—	671	—
<b>Total assets</b>		<b>440,011</b>	<b>411,039</b>	<b>27,888</b>	<b>1,084</b>
Derivatives financial liabilities	25	1,681	—	1,681	—
<b>Total Liabilities</b>		<b>1,681</b>	<b>—</b>	<b>1,681</b>	<b>—</b>

The fair value of current financial assets and other financial liabilities is measured by taking into consideration market parameters at the balance sheet date, using valuation techniques widely accepted in the financial business environment.

The fair value of foreign currency derivatives (forward contracts, currency swaps and options) and interest rate swaps is determined by considering the prevailing foreign currency exchange rate and interest rates, as applicable, at the balance sheet date.

The value of cash and cash equivalents usually approximates fair value due to the short maturity of these instruments, which consist of bank current accounts.

No borrowings of the Group are listed debt.

There are no transfers between Level 1, Level 2 and Level 3 during the year ended December 31, 2021. During the nine months ended September 30, 2022, the transfer between Level 3 and Level 1 for "Financial assets - investment FVTPL" is related to the distribution of the shares in Rani Therapeutics Holdings, listed on NASDAQ, from the investment fund Biologix Partners LP.

The fair value of the loans accounted for at amortized cost approximates their carrying amounts as of September 30, 2022, and December 31, 2021.

## 27. Employee benefits

Employee benefits are analyzed as follows:

	At September 30,	At December 31,
	2022	2021
(EUR thousand)		
Employee severance pay	4,882	5,895
Jubilee benefits	253	253
Other post-employment plans	835	699
Long term incentive plan	148	3,653
Stock grant plan	1,353	1,353
Shares based compensation	479	—
<b>Total employee benefits</b>	<b>7,950</b>	<b>11,853</b>

### Long-term Incentive plan

In order to align the interests of management with those of the Shareholders, the Group established a medium/ long-term incentive plan linking remuneration and performance. The Board of Directors approved a compensation plan called the "Long-term Incentive plan" for the 2020-2023. The four-year plan involved a select number of top Management and/ or key people and was based on achieving certain key performance indicators under the Group's long-term industrial plan targets.



On April 11, 2022 the Board of Directors approved an amendment to the "Restricted Stock Grant Plan Stevanato Group S.p.A. 2021-2027", in order to allow the entry of new beneficiaries in 2022, previously involved in the compensation plan called "Long Term Incentive 2020-2023". In accordance with specific rules, existing and new beneficiaries relating to the first vesting period will coexist until 2022 under the "Restricted Stock Grant Plan Stevanato Group S.p.A. 2021-2027". Through such amendment, beneficiaries of the Long Term Incentive 2020-2023 were offered the possibility of becoming beneficiaries of the "Restricted Stock Grant Plan Stevanato Group S.p.A. 2021-2027" in 2022 by using the rights deriving from the participation in the Long-Term Incentive 2020-2023 in the meantime accrued to them, but providing, that the free of charge transfer of the property of a certain number of Stevanato Group S.p.A. shares should have been done after the end of the First Vesting Period, after having verified the actual achievement of the Performance Objectives (in terms of consolidated revenue and EBITDA) set for such vesting period and the continuation of the employment relationship.

The letters of assignment of shares were issued to beneficiaries on May 12, 2022 and from that date the amendment of the incentive plans produced its accounting effects.

#### **Restricted Stock Grant Plan 2021-2027**

At the Shareholders' Meeting of Stevanato Group held on March 4, 2021, a share-based incentive plan, referred to as the "Restricted Stock Grant Plan 2021-2027" was approved. This plan includes individuals who play a strategic role in the Group related to the economic and strategic development of the Group and aligns their interests to those of the shareholders and other stakeholders of the Company, during the period between January 1, 2021 and December 31, 2026.

The Stock Grant Plan originally provided for three two-year vesting periods, between January 1, 2021 and December 31, 2022 (First Vesting Period), January 1, 2023 and December 31, 2024 (Second Vesting Period), January 1, 2025 and December 2026 (Third Vesting Period). On April 11, 2022 the Board of Directors approved an amendment to the "Restricted Stock Grant Plan Stevanato Group S.p.A. 2021-2027", to allow the entry in 2022 of new beneficiaries, previously involved in the compensation plan called "Long Term Incentive 2020-2023". Through such amendment, (i) the total duration of the "Restricted Stock Grant Plan Stevanato Group S.p.A. 2021-2027" was limited to the First Vesting Period only and (ii) the beneficiaries were divided into two categories: the initial beneficiaries and the new beneficiaries for which specific rules apply.

At the beginning of the vesting period, a certain number of Stevanato Group ordinary shares – linked with the achievement of specific targets in terms of consolidated revenue and EBITDA within the end of the Vesting Period – was assigned free of charge to the initial beneficiaries. For the EBITDA definition, please refer to section "Key Indicators of Performance and Financial Condition" of Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations below. The assigned shares will be registered to a Trustee company and will be subject to the prohibition to sell and to the selling commitment in accordance to a one-year lock-up period.

The transfer of ownership of the shares will be finalized after each initial beneficiary signs an agreement which binds the beneficiaries to re-sell to Stevanato Group, fully or partially, the Shares assigned to them in case the targets provided for the vesting period in relation to which the shares were assigned should not be totally or partially achieved. A similar obligation is provided if, within the end of the vesting period, the employment relationship terminates.

In the event of over-performances related to the Key Indicators of Performance, initial beneficiaries will be granted, free of charge, an additional number of Stevanato Group shares related to the vesting period in which the targets were exceeded and the additional shares assigned will be subject to the time-limited prohibition to sell.

On June 3, 2021 a total of 236,988 ordinary shares, which were previously held in treasury, were assigned to the initial beneficiaries of the plan.

On May 12, 2022, Stevanato Group sent, to the new beneficiaries of shares, a letter granting them the right to obtain the transfer free of charge of a certain number of shares if the targets, in terms of consolidated revenue and EBITDA provided for the vesting period in relation to which the shares were assigned, are achieved. New beneficiaries are individuals who play a strategic role in the Group, including its economic and strategic development, and the above right to transfer shares (subject to certain conditions) aligns their

interests to those of the shareholders and other stakeholders of the Company, during the period between January 1, 2021 and December 31, 2026. The effectiveness of the rights attributed to each of the new beneficiaries of shares is conditional upon the verification by the Stevanato Group's administrative body of the degree of achievement of the performance target provided in relation to the first vesting period after the end of the first vesting period. On the basis of this assessment the number of shares indicated in the letter of attribution of rights can be reduced based on the degree of target achievement.

## 28.Provisions

The balances as of September 30, 2022, are detailed below:

	Provision for Warranty	Decommissioning	Provision for legal and sundry risks	Provision for agents and directors severance indemnity	Total
	(EUR thousand)				
<b>At January 1, 2022</b>	<b>1,061</b>	<b>591</b>	<b>572</b>	<b>1,275</b>	<b>3,499</b>
Arising during the period	252	146	1,117	39	1,554
Utilized	—	—	(8)	(265)	(273)
Unused amounts reversed	—	—	—	—	—
Exchange rate difference	—	(28)	161	—	133
<b>At September 30, 2022</b>	<b>1,313</b>	<b>709</b>	<b>1,841</b>	<b>1,049</b>	<b>4,912</b>
Current	—	—	—	—	—
Non-current	1,313	709	1,841	1,049	4,912

The Provision for Warranty represents the best estimate of commitments given by the Group for contractual, legal, or constructive obligations arising from product warranties given for a specified period of time. Such provisions are recognized on shipment of the goods to the customers. The Provision for Warranty is estimated on the basis of the Group's past experience and contractual terms. Related costs are recognized within cost of sales.

As of September 30, 2022, the Group's Provision for Legal and Sundry Risks in connection with taxation related to personnel severance amounted to EUR 752 thousand and a provision for workers compensation insurance for EUR 365 thousand.

The Provision for Legal and Sundry Risks represents management's best estimate of the expenditures expected to be required to settle on otherwise resolve legal proceedings and disputes.

## 29.Other non-current liabilities

Other non-current liabilities as of September 30, 2022, and December 31, 2021, amounted to EUR 15,998 thousand and EUR 1,808 thousand, respectively. The increase was related to an advance payment from the U.S. Biomedical Advanced Research and Development Authority (BARDA) of approximately EUR 14,173 thousand, which reflects a partial payment for glass conversion machines in Fishers, Indiana, to help strengthen domestic capabilities in the U.S. for national defense readiness and preparedness programs for current and future public health emergencies. In addition to that, the increase reflects holiday pay for Danish companies' employees following the transition to the new Danish Holiday Act that started in 2019.

## 30.Trade payables and other current liabilities

Trade payables amounted to EUR 203,076 thousand at September 30, 2022 compared to EUR 164,787 thousand at December 31, 2021 and other current liabilities amounted to EUR 74,782 thousand at September 30, 2022 compared to EUR 65,813 thousand at December 31, 2021, both are entirely due within one year. The carrying amount of trade payables is considered to be equivalent to their fair value.

### 31.Contract liabilities and advances from customers

Contract liabilities and advances from customers are as follows:

	At September 30, 2022	At December 31, 2021
	(EUR thousand)	
Contract Liabilities	23,111	18,771
Advances from customers	26,793	23,616
<b>Total contract liabilities and advances from customers</b>	<b>49,904</b>	<b>42,387</b>
Current	49,904	42,387
Non-current	—	—

Contract liabilities relate to revenue earned from ongoing customer-specific construction contracts in the Engineering Segment and in the in-vitro diagnostic business, which is part of the Biopharmaceutical and Diagnostic Solutions Segment. The Group has contract net liabilities of EUR 23,111 thousand and EUR 18,771 thousand as of September 30, 2022, and as of December 31, 2021, respectively. Contract liabilities gross amounts to EUR 52,211 thousand (EUR 27,504 thousand as of December 31, 2021), net of invoices issued of EUR 75,322 thousand (EUR 46,275 thousand as of December 31, 2021).

Advances from customers relate to sales whose revenue are recognized at a point in time.

### 32.Related party disclosures

According to IAS 24, the related parties of the Group are entities and individuals capable of exercising control, joint control or significant influence over the Group and its subsidiaries, companies belonging to the Stevanato Group S.p.A., the controlling company Stevanato Holding S.r.l., unconsolidated subsidiaries of the Group and associates. In addition, members of Stevanato Group's Board of Directors and executives with strategic responsibilities and their families are also considered related parties. The Group carries out transactions with related parties on commercial terms that are normal in the respective markets, considering the characteristics of the goods or services involved.

Note 4 provides information about the Group's structure, including details of the subsidiaries and the holding company. Transaction with related parties refer to:

- service fees and rentals paid to Winckler & Co Ltd., the company whose owner holds minority interests in the subsidiary Ompi of Japan Co Ltd;
- rentals paid to SFEM Italia S.r.l., controlled by the Stevanato family;
- the purchase of products and rentals paid to Società Agricola Stella S.r.l., fully controlled by SFEM Italia S.r.l. until November 12, 2021 and then 51% controlled by Stevanato Holding S.r.l. and 49% controlled by SFEM Italia S.r.l.;
- for the nine months ended September 30, 2021, consulting services provided by MJB Consultants LLC and Progenitor Capital Partners LLC, whose beneficial owners are Board members in Stevanato Group S.p.A.;
- for the nine months ended September 30, 2021, revenue for drug containment systems from the affiliate Swissfillon AG (derecognized on October 22, 2021);

- consulting services provided by Studio Legale Spinazzi Azzarita Troi, whose beneficial owner is a Board member in Stevanato Group S.p.A.;
- industrial rentals paid to E & FKH Ejendomme ApS, whose beneficial owners are family members of a Board member in the subsidiary SVM Automatik A/S;
- rentals paid to members of the Stevanato family;
- in 2018 and 2019 SE Holdings Co Ltd., the minority shareholder of the subsidiary Ompi of Japan Co Ltd., disbursed loans amounting respectively to JPY 73.5 million and JPY 49.0 million;
- donations to the Stevanato Foundation, owned by the Stevanato family. The Foundation exclusively pursues the aims of social solidarity, philanthropy and charity, operating in the fields of social and socio-medical assistance, education and training as well as cultural and educational activities and scientific research. The Foundation intervenes in support of children and young people in situations of serious difficulty due to their illnesses, the distress of their families or other situations that may affect their health or growth;
- during the fiscal year ended December 31, 2021, Stevanato Group made loans aggregating approximately EUR 447 thousand to two senior executives in order for them to pay taxes arising from shares granted to them under our restricted stock grant plan. At the time the loans were made, management believed that these loans were permissible and did not violate Section 13(k) of the Exchange Act. Upon being advised that such loans were impermissible the two executives repaid such loans in full, after the end of the first quarter of 2022. As a result of this inadvertent violation, the Board adopted a policy regarding loans or advances to any Executive Officer or Director of the Company. The policy provides that “The Company shall not directly or indirectly, including through any subsidiary, extend or maintain credit to, or arrange for the extension of credit, or renew an extension of credit, in the form of a personal loan to or for any Director or Executive Officer (or equivalent thereof) of the Company or any subsidiary of the Company.”;
- consulting services provided by C.T.S. Studio AS, whose beneficial owner is a Board member in the sub-holding Stevanato Group International AS;
- revenue from the sale of drug containment systems to Incog BioPharma Services, Inc, a U.S. based biopharma services company, in which by SFEM Italia S.r.l. holds a controlling stake.

Transactions with related parties also include compensation to directors and managers with strategic responsibilities.

The amounts of transactions with related parties recognized in the Interim Consolidated Income Statement and the related assets and liabilities are as follows:

	For the three months ended September 30,						For the nine months ended September 30,					
	2022			2021			2022			2021		
	Revenues	Costs*	Net financial expenses	Revenues	Costs*	Net financial expenses	Revenues	Costs*	Net financial expenses	Revenues	Costs*	Net financial expenses
	(EUR thousand)			(EUR thousand)			(EUR thousand)			(EUR thousand)		
<b>Associated companies</b>												
Swissfillon AG	—	—	—	193	—	—	—	—	—	565	—	(10)
<b>Parent company</b>												
Stevanato Holding Srl	—	—	—	4,426	—	—	—	—	—	4,426	—	—
<b>Other related parties</b>	256	2,591	2	—	1,745	—	314	8,327	2	—	(2,942)	(17)
<b>Total transactions with related parties</b>	<u>256</u>	<u>2,591</u>	<u>2</u>	<u>4,619</u>	<u>1,745</u>	<u>—</u>	<u>314</u>	<u>8,327</u>	<u>2</u>	<u>4,991</u>	<u>(2,942)</u>	<u>(27)</u>

\* Costs include cost of sale, selling, general administrative costs and other expenses net.

	As at September 30, 2022				As at December 31, 2021			
	Trade receivables	Trade payables	Other assets or liabilities	Financial assets or liabilities	Trade receivables	Trade payables	Other assets or liabilities	Financial assets or liabilities
	(EUR thousand)				(EUR thousand)			
<b>Parent Company:</b>								
Stevanato Holding	—	—	—	—	—	—	—	—
<b>Other related parties</b>	256	116	—	(869)	393	238	—	(493)
<b>Total transactions with related parties</b>	<u>256</u>	<u>116</u>	<u>—</u>	<u>(869)</u>	<u>393</u>	<u>238</u>	<u>—</u>	<u>(493)</u>

### 33.COVID-19 Pandemic

Stevanato Group has been in the vaccine business for decades, serving as a partner for the distribution of a variety of vaccines worldwide. In 2020, the global COVID-19 pandemic caused both governments and private organizations to implement numerous measures seeking to contain the spread of the virus. These measures impacted and are expected to continue to impact the Group business and operations in several ways.

The Group believes that it is likely that the unfavorable impacts from COVID-19 on production and operational capabilities will be short term and abate as countries around the world continue their response to the pandemic. The unfavorable impacts included: (i) a temporary decrease in the sales of certain non-COVID-19 products as a result of traditional healthcare procedures being postponed and the diversion of our production capacity to support the rollout of the COVID-19 vaccine worldwide, (ii) labor absenteeism; (iii) disruptions to production lines; (iv) delays in, and increased costs of, raw materials, logistics, and other input costs, and (v), for the year ended December 31, 2021, increased SG&A costs related to employee bonuses to recognize and reward general efforts to ensure business continuity during the pandemic. However, COVID-19 also provided an uplift to the Group's business with an acceleration of revenue from the sale of syringes and vials for vaccination programs globally. Stevanato Group has been supplying: (i) glass vials and syringes to approximately 90% of currently marketed vaccine programs, according to our estimates based on public information (WHO, EMA, FDA); and (ii) plastic diagnostic consumables for the detection and diagnosis of COVID-19.

Currently, the Group expects revenue for syringes, vials and related products and services that were specifically related to COVID-19, to decrease for the fiscal year 2022 from the elevated levels the Group experienced in fiscal year 2021. The Group still expects to benefit from sales related to COVID-19 products and services, but to a lesser extent, as governments worldwide continue to support and promote COVID-19 vaccine programs. At the present time, the Group is working with certain customers who are contemplating a shift from multi-dose formats to single dose formats for the administration of COVID-19 vaccines. The Group is also working with customers on adjustments and modifications to orders related to COVID-19 as customer needs evolve. Longer-term, there remains uncertainty around the magnitude of the continued impact of COVID-19 and the demand for our solutions in connection thereto. Many scientists predict that COVID-19 will eventually transition to an endemic state. While timing of this transition is difficult to predict, when and if such transition does occur, it may result in a continued need for the Group's products and services that support COVID-19 and might be integrated into the standard vaccine business in the coming years.

### **34. Impact of war in Ukraine**

On February 24, 2022, Russia launched a military invasion of Ukraine. As of today, active conflict is underway in and impacting several major Ukrainian cities.

The military actions undertaken by Russian military forces against Ukraine resulted in the imposition of financial and economic sanctions by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia and Belarus. Such sanctions, together with any additional measure that may be adopted in connection with this situation, may, in various ways, constrain Russia and Ukraine related transactions.

Such military actions against Ukraine, as well as the measures adopted, or that may be adopted, by other countries in response to these events, including new and stricter sanctions by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia and Belarus (or other countries that were to become involved), could have a material adverse effect on Group operations. The Group is monitoring the conflict, but cannot predict whether this situation, which is unfolding in real-time, may escalate and result in broader economic and security conditions or in material implications for its business. None of the Group's operational locations are located in Russia or the Ukraine.

Primarily as a result of the Russian-Ukrainian conflict, gas and electricity prices have risen dramatically and affected Group margins, but the Group has not faced any material disruption in accessing natural gas for its operations to date. The Group's operations in Italy have the highest gas consumption across its European operations.

According to widely published press reports, the Italian government has taken steps to shore up its natural gas supplies and lower its dependence on Russian supplies. Italy has signed agreements with several other countries to diversify the country's natural gas sources and Algeria is now the largest supplier of natural gas to Italy. On October 2, 2022, the Italian government stated that gas storage levels in Italy were estimated to be at more than 90%. In addition, the Group believes it may be eligible for priority status since its business operations are devoted to the delivery of mission-critical pharmaceutical products.

However, the current conflict and the imposition of financial and economic sanctions following the invasion may negatively impact the Group's ability to source gas at commercially reasonable terms, or at all.

### **35. Events after the reporting period**

The Group has evaluated subsequent events through November 4, 2022, which is the date the Interim Condensed Consolidated Financial Statements were authorized for issuance and concluded that there is nothing material to report.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

*Our estimates and forward-looking statements are mainly based on our current expectations and estimates of future events and trends, which affect or may affect our businesses and operations. Although we believe that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to numerous risks and uncertainties and are made in light of information currently available to us. Many important factors may adversely affect our results as indicated in forward-looking statements.*

*For additional information, refer to the risk factors discussed under "Item 1A. Risk Factors" below and in our other filings with the U.S. Securities and Exchange Commission. You should read this discussion and analysis completely and with the understanding that our actual future results may be materially different and worse from what we expect.*

### Overview

We are a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. We deliver an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Our core capabilities in scientific research and development, our commitment to technical innovation and our engineering excellence are central to our ability to offer value added solutions to our clients.

We have secured a leadership position within the drug development and delivery value chain through our investment in research and development and the expansion of our global footprint and capabilities. Over our 70-year history, we have earned a leading reputation for high quality and reliability that has enabled us to become a partner of choice for more than 700 companies globally, including 41 of the top 50 pharmaceutical companies (which comprise all of the top 15) and eight of the top ten in-vitro diagnostic companies, as measured by 2020 revenue, according to data collected by Global Data. We also serve 15 of the top 20 biotechnology companies by market capitalization in the NASDAQ Biotechnology Index and over 100 biotechnology customers in total.

Our priority is to provide flexible solutions that preserve the integrity of pharmaceutical products and enable our customers to deliver safe and effective treatments to patients while reducing time to market, total cost of ownership (i.e., logistics, drug product waste, storage and personnel costs) and supply chain risk. We achieve this by developing our products in close collaboration with our customers, leveraging our scientific research capabilities, technical expertise and engineering and manufacturing excellence to meet their quality requirements. For example, under our Exclusive Collaboration Agreement with Owen Mumford Ltd. relating to our Aidaptus disposable autoinjector platform, which we announced on May 4, 2022, we are harnessing the full breadth of services to deliver the Aidaptus auto injector.

Our solutions are highly integrated with the development, production and commercialization processes of our customers. In addition to manufacturing drug containment and delivery solutions, we provide a full set of services across all stages of drug development, from pre-clinical to clinical and commercialization. We also engineer machinery and equipment for the production of drug containment and delivery systems that can be integrated into both our customers' and our own manufacturing processes. Our involvement at each stage of a drug's life cycle, together with the breadth of our offering, enables us to serve as a one-stop-shop for our customers, which we believe represents a significant competitive advantage.

We operate across the healthcare industry and serve some of its fastest growing segments, including biologics (including GLP-1s, monoclonal antibodies and mRNA applications), biosimilars, vaccines and molecular diagnostics. As a result of how closely integrated we are in the drug production and delivery supply chain, we are well-positioned to benefit from multi-year, secular trends within our target industries, such as increases in demand resulting from pharmaceutical innovation, acceleration and expansion of vaccination programs, growth in biologics/biosimilars, self-administration of medicines, aging demographics, increasing quality standards and regulation and a shift towards outsourcing non-core functions by our customers.

We estimate that our total addressable market, based on our current offering, exceeded \$13 billion in terms of revenue generated by all market participants in 2021, and consists of biopharmaceutical injectables and in-vitro diagnostic products. Within each of these markets, we operate in some of the fastest growing segments, including pre-fillable syringes, drug delivery systems, molecular diagnostics and assembly equipment. We believe there are opportunities to further expand our addressable markets, including by targeting (i) complementary containment solutions; (ii) additional delivery systems; (iii) complementary engineering solutions; and (iv) after sales support and services.

We operate our business in two segments:

- Biopharmaceutical and Diagnostic Solutions, which includes the products, processes and services developed and provided in connection with the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables; and

- Engineering, which includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes (i.e., machinery for assembly, visual inspection, packaging and serialization and glass converting).

In the nine months ended September 30, 2022, and 2021, we generated 82% and 83% of total sales from our Biopharmaceutical and Diagnostic Solutions segment, respectively, and 18% and 17% from our Engineering segment, respectively.

We refer to our premium products in the Biopharmaceutical and Diagnostic Solutions segment as our “high-value” solutions. High-value solutions are wholly owned, internally developed products, processes and services for which we hold intellectual property rights or have strong proprietary know-how, and that are characterized by particular complexity and high performance. Our high-value solutions deliver significant benefits to customers including higher quality, reduced time-to-market and reduced total cost of ownership. Today, only about 5% of the vial market and less than 5% of the cartridge market has transitioned to a ready-to-use format but we are currently witnessing a real desire by customers to transition to ready-to-use formats to gain efficiencies. Among our key high-value solutions is our EZ-Fill® line of ready-to-fill injectable products, which can be customized to meet clients’ needs. For additional information on EZ-Fill® see “Business—Business Segments—Biopharmaceutical and Diagnostic Solutions— Drug Containment Systems (DCS)” of our Annual Report on Form 20-F/A for the year ended December 31, 2021.

We have nine production plants for manufacturing and assembling pharmaceutical and healthcare products across Europe (Italy, Germany and Slovakia) and the rest of the world (Brazil, China, Mexico and the United States), five plants for the production of machinery and equipment (Italy and Denmark), two sites for analytical services (Italy and the United States) and two commercial offices (Japan and the United States). Our manufacturing facilities in Mexico (serving the U.S. market), China and Brazil are greenfield operations established by us. Our manufacturing facilities in Slovakia, Denmark, Germany and the United States were acquired in strategic transactions over the past 15 years. Our global footprint, together with our proprietary, highly standardized manufacturing systems and processes, allow us to provide quality consistent products and services to our customers in more than 70 countries.

The Group is expanding its global industrial footprint with the establishment of two new regional hubs in Fishers, Indiana, United States and Zhangjiagang, China, primarily to add capacity in its premium EZ-Fill® products to diversify its product supply and improve proximity to customers.

## Highlights

### Consolidated Income Statement Data

	(Amounts in € millions, except as indicated otherwise)							
	For the three months ended September 30,		Change		For the nine months ended September 30,		Change	
	2022	2021		%	2022	2021		%
Net Revenues	245.3	214.5		14.4 %	691.6	611.3		13.1 %
Gross Profit	77.5	63.3		22.4 %	219.6	192.4		14.1 %
Operating Profit	47.5	28.2		68.4 %	129.3	118.8		8.8 %
Profit Before Tax	46.0	22.4		105.4 %	123.8	112.0		10.5 %
Net Profit attributable to:								
Equity holders of the parent	36.2	18.6		94.6 %	94.5	89.6		5.5 %
Non-controlling interest	0.1	—		—	0.2	—		—
Basic earnings per common share (in €)	0.14	0.07		100.0 %	0.36	0.36		—
Diluted earnings per common share (in €)	0.14	0.07		100.0 %	0.36	0.36		—

### Consolidated Statement of Financial Position Data



	(Amounts in € millions, except as indicated otherwise)		
	At September 30, 2022	At December 31, 2021	Change €
<b>Assets</b>			
Total current assets	887.6	866.0	21.6
Total non-current assets	740.6	552.9	187.7
<b>Total assets</b>	<b>1,628.2</b>	<b>1,418.9</b>	<b>209.3</b>
<b>Liabilities and equity</b>			
Total current liabilities	443.7	338.6	105.1
Total non-current liabilities	221.4	238.6	(17.2 )
<b>Total liabilities</b>	<b>665.1</b>	<b>577.2</b>	<b>87.9</b>
Equity	963.1	841.7	121.4
<b>Total liabilities and equity</b>	<b>1,628.2</b>	<b>1,418.9</b>	<b>209.3</b>

#### *COVID-19 pandemic update*

Stevanato Group has been in the vaccine business for decades, serving as a partner for the distribution of a variety of vaccines worldwide. In 2020, the global COVID-19 pandemic caused both governments and private organizations to implement numerous measures seeking to contain the spread of the virus. These measures have impacted the Group business and operations in several ways.

The Group believes that it is likely that the unfavorable impacts from COVID-19 on production and operational capabilities will be short term and abate as countries around the world continue their response to the pandemic. The unfavorable impacts included: (i) a temporary decrease in the sales of certain non-COVID-19 products as a result of traditional healthcare procedures being postponed and the diversion of our production capacity to support the rollout of the COVID-19 vaccine worldwide; (ii) labor absenteeism; (iii) disruptions to production lines; (iv) delays in, and increased costs of, raw materials, logistics, and other input costs; and (v), for the year ended December 31, 2021, increased SG&A costs related to employee bonuses to recognize and reward general efforts to ensure business continuity during the pandemic.

However, COVID-19 also provided an uplift to the Group's business with an acceleration of revenue from the sale of syringes and vials for vaccination programs globally. Stevanato Group has been supplying: (i) glass vials and syringes to approximately 90% of currently marketed vaccine programs, according to our estimates based on public information (WHO, EMA, FDA); and (ii) plastic diagnostic consumables for the detection and diagnosis of COVID-19. Currently, the Group expects revenue for syringes, vials and related products and services that were specifically related to COVID-19, to decrease for the fiscal year 2022 from the elevated levels the Group experienced in fiscal year 2021. The Group still expects to benefit from sales related to COVID-19 products and services, but to a lesser extent, as governments worldwide continue to support and promote COVID-19 vaccine programs. At the present time, the Group is working with certain customers who are contemplating a shift from multi-dose formats to single dose formats for the administration of COVID-19 vaccines. The Group is also working with customers on adjustments and modifications to orders related to COVID-19 as customer needs evolve. Longer-term, there remains uncertainty around the magnitude of the continued impact of COVID-19 and the demand for our solutions in connection thereto. Many scientists predict that COVID-19 will eventually transition to an endemic state. While timing of this transition is difficult to predict, when and if such transition does occur, it may result in a continued need for the Group's products and services that support COVID-19 and might be integrated into the standard vaccine business in the coming years.

#### *2022 First nine months challenges*

In the first nine months of 2022, we confronted a number of challenges linked, in part, to the COVID-19 pandemic and, in part, to the conflict between Russia and Ukraine.

The military actions undertaken by Russian military forces against Ukraine resulted in the imposition of financial and economic sanctions by the European Union, the U.S., the United Kingdom and certain other countries and organizations against officials, individuals, regions, and industries in Russia and Belarus. As a result, primarily of the Russian-Ukrainian conflict, gas prices have risen dramatically and affected Group margins. However, Stevanato Group has not faced any difficulties in accessing natural gas for its operations to date.

The increased demand for electrical components, coupled with COVID-19 lockdowns in China, has impacted global supply chains, which were already under strain. While this has caused a temporary disruption in the supply of the manufacturing parts that we use, our ability to source from multiple suppliers, order materials in advance, and keep excess raw materials and inventory on hand, limited the impact on our business of these supply chain challenges.

As a consequence of the above, during the first nine months of 2022, there has been a trend of increasing inflation, the effects of which we may be able to offset (in whole or in part) by adjusting our prices.

## Key Indicators of Performance and Financial Condition

### Non-GAAP Financial Measures

We monitor and evaluate our operating and financial performance using several non-GAAP financial measures, including: Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt) and Capital Employed. We believe that these non-GAAP financial measures provide useful and relevant information regarding our performance and improve our ability to assess our financial condition. While similar measures are widely used in the industry in which we operate, the financial measures we use may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.

### Constant Currency Revenue

Constant Currency Revenue is defined as revenue excluding the impact of fluctuations in currency exchange rates. Constant Currency Revenue is presented to aid management in their analysis of the performance of the Group and to assist in the comparison of our performance with the prior periods and that of our competitors. We believe providing constant currency information provides valuable supplemental information regarding our results of operations. We calculate constant currency amounts by converting our current period local currency revenue using the prior period foreign currency average exchange rates and comparing these adjusted amounts to our prior period reported results. This calculation may differ from similarly titled measures used by others and, accordingly, the constant currency presentation is not meant to substitute recorded amounts presented in conformity with IFRS as issued by the IASB, nor should such amounts be considered in isolation. The following tables set forth the calculation of Constant Currency Revenue for the three and the nine months ended September 30, 2022 and provide a reconciliation to the most comparable IFRS measure, Revenue.

	(Amounts in € millions, except as indicated otherwise)				Consolidated
	Biopharmaceutical and Diagnostic Solutions		Engineering	Consolidated	
For the three months ended September 30, 2022	High-Value Solutions	Other containment and delivery solutions	Total Biopharmaceutical and Diagnostic Solutions	Total Engineering	Total Consolidated
Reported Revenue	74.4	132.7	207.1	38.2	245.3
Effect of changes in currency translation rates	(2.4 )	(5.7 )	(8.1 )	0.0	(8.1 )
<b>Constant Currency Revenue</b>	<b>72.0</b>	<b>127.0</b>	<b>199.0</b>	<b>38.2</b>	<b>237.2</b>

For the nine months ended September 30, 2022	(Amounts in € millions, except as indicated otherwise)				
	Biopharmaceutical and Diagnostic Solutions			Engineering	Consolidated
	<i>High-Value Solutions</i>	<i>Other containment and delivery solutions</i>	Total Biopharmaceutical and Diagnostic Solutions	Total Engineering	Total Consolidated
Reported Revenue	206.0	362.1	568.1	123.4	691.6
Effect of changes in currency translation rates	(6.4)	(13.4)	(19.8)	0.0	(19.8)
<b>Constant Currency Revenue</b>	<b>199.6</b>	<b>348.7</b>	<b>548.3</b>	<b>123.4</b>	<b>671.8</b>

Change in revenues at constant currency	(Amounts in € millions, except as indicated otherwise)				
	Biopharmaceutical and Diagnostic Solutions			Engineering	Consolidated
	<i>High-Value Solutions</i>	<i>Other containment and delivery solutions</i>	Total Biopharmaceutical and Diagnostic Solutions	Total Engineering	Total Consolidated
Constant Currency Revenue for the three months ended September 30, 2022	72.0	127.0	199.0	38.1	237.2
Reported Revenue for the three months ended September 30, 2021	48.4	124.3	172.8	41.8	214.5
<b>Change in revenue at constant currency</b>	<b>23.6</b>	<b>2.7</b>	<b>26.2</b>	<b>(3.7)</b>	<b>22.6</b>
<b>% Change in revenue at constant currency</b>	<b>48.7 %</b>	<b>2.2 %</b>	<b>15.2 %</b>	<b>(8.9) %</b>	<b>10.5 %</b>

Change in revenues at constant currency	(Amounts in € millions, except as indicated otherwise)				
	Biopharmaceutical and Diagnostic Solutions			Engineering	Consolidated
	<i>High-Value Solutions</i>	<i>Other containment and delivery solutions</i>	Total Biopharmaceutical and Diagnostic Solutions	Total Engineering	Total Consolidated
Constant Currency Revenue for the nine months ended September 30, 2022	199.6	348.7	548.3	123.4	671.8
Reported Revenue for the nine months ended September 30, 2021	141.4	366.7	508.2	103.2	611.3
<b>Change in revenue at constant currency</b>	<b>58.2</b>	<b>(18.0)</b>	<b>40.1</b>	<b>20.2</b>	<b>60.4</b>
<b>% Change in revenue at constant currency</b>	<b>41.2 %</b>	<b>(4.9) %</b>	<b>7.9 %</b>	<b>19.6 %</b>	<b>9.9 %</b>

*EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin*

EBITDA is defined as net profit before income tax expenses, net financial expenses, including share of profit of associates, amortization and depreciation. Adjusted EBITDA is defined as EBITDA as adjusted for certain income and costs expected to occur infrequently, and that management considers not reflective of ongoing operational activities of the Company. EBITDA is presented to aid management in their analysis of the performance of the Group and to assist in the comparison of our performance with that of our competitors. Adjusted EBITDA is provided in order to present how the underlying business has performed excluding the impact of certain non-recurring items, which may alter the underlying performance and impair comparability of results between periods.

The following table sets forth the calculation of EBITDA and Adjusted EBITDA for the three and the nine months ended September 30, 2022, and 2021, and provides a reconciliation of these non-GAAP measures to the most comparable IFRS measure, Net Profit. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA for a period by total revenue for the same period.

	(Amounts in € millions, except as indicated otherwise)					
	For the three months ended September 30,		Change %	For the nine months ended September 30,		Change %
	2022	2021		2022	2021	
Net Profit	36.3	18.6	95.2 %	94.7	89.7	5.6 %
Income Taxes	9.8	3.8	157.9 %	29.1	22.3	30.5 %
Finance Income	(6.8)	(2.1)	223.8 %	(17.2)	(6.4)	168.8 %
Finance Expenses	8.2	8.0	2.5 %	22.7	13.7	65.7 %
Share of profit of an associate	—	(0.2)	(100.0)%	—	(0.5)	(100.0)%
<b>Operating Profit</b>	<b>47.5</b>	<b>28.2</b>	<b>68.4 %</b>	<b>129.3</b>	<b>118.8</b>	<b>8.8 %</b>
Depreciation and Amortization	16.7	14.9	12.1 %	47.8	41.3	15.7 %
<b>EBITDA</b>	<b>64.2</b>	<b>43.2</b>	<b>48.6 %</b>	<b>177.1</b>	<b>160.1</b>	<b>10.6 %</b>
Non-recurring items	1.6	8.2	(80.5)%	4.6	(0.7)	(75.1)%
<b>Adjusted EBITDA</b>	<b>65.8</b>	<b>51.4</b>	<b>28.0 %</b>	<b>181.7</b>	<b>159.4</b>	<b>13.9 %</b>
<b>Adjusted EBITDA Margin</b>	<b>26.8 %</b>	<b>24.0 %</b>	<b>11.7 %</b>	<b>26.3 %</b>	<b>26.1 %</b>	<b>0.7 %</b>

*Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Net Profit and Adjusted Diluted EPS*

Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS represent respectively Operating Profit, Net Profit and Diluted EPS as adjusted for certain income and costs expected to occur infrequently, and that management considers not reflective of ongoing operational activities. Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS are provided in order to present how the underlying business has performed excluding the impact of the adjusting items, which may alter the underlying performance and impair comparability of results between the periods.

The following tables set forth the calculation of Adjusted Operating Profit for the three and the nine months ended September 30, 2022, and 2021. Adjusted Operating Profit margin is calculated by dividing Adjusted Operating Profit for a period by total revenue for the same period.

For further information on non-recurring items, see “Cost of Sales”, “General and Administrative Expenses”, and “Income Taxes” below.

For the three months ended September 30, 2022	(Amounts in € millions, except as indicated otherwise)				
	EBITDA	Operating Profit	Income Taxes	Net Profit	Diluted EPS
Reported	64.2	47.5	9.8	36.3	0.14
Adjusting items:					
Start-up costs new plants <sup>(1)</sup>	1.6	1.6	0.2	1.4	0.01
<b>Adjusted</b>	<b>65.8</b>	<b>49.1</b>	<b>10.0</b>	<b>37.7</b>	<b>0.14</b>
<b>Adjusted Margin</b>	<b>26.8 %</b>	<b>20.0 %</b>	—	—	—

For the nine months ended September 30, 2022	(Amounts in € millions, except as indicated otherwise)				
	EBITDA	Operating Profit	Income Taxes	Net Profit	Diluted EPS
Reported	177.1	129.3	29.1	94.7	0.36
Adjusting items:					
Start-up costs new plants <sup>(1)</sup>	4.6	4.6	1.1	3.5	0.01
<b>Adjusted</b>	<b>181.7</b>	<b>133.9</b>	<b>30.2</b>	<b>98.2</b>	<b>0.36</b>
<b>Adjusted Margin</b>	<b>26.3 %</b>	<b>19.4 %</b>	—	—	—

For the three months ended September 30, 2021	(Amounts in € millions, except as indicated otherwise)				Diluted EPS
	EBITDA	Operating Profit	Income Taxes	Net Profit	
Reported	43.2	28.2	3.8	18.6	0.07
Adjusting items:					
Restructuring and related charges <sup>(2)</sup>	0.2	0.2	0.1	0.1	0.00
Incentive Plans Settlement <sup>(3)</sup>	0.0	0.0	0.0	0.0	0.00
IPO costs reversed (booked as at March 31, 2021) <sup>(4)</sup>	0.7	0.7	0.2	0.5	0.00
Out-of-cycle bonus to personnel <sup>(5)</sup>	6.7	6.7	1.8	4.9	0.02
Foreign exchange loss for derivatives on IPO proceeds <sup>(6)</sup>	—	—	1.0	3.3	0.01
Start-up costs U.S. plant <sup>(1)</sup>	0.6	0.6	0.2	0.5	0.00
Patent Box <sup>(7)</sup>	—	—	1.6	(1.6)	(0.01)
<b>Adjusted</b>	<b>51.4</b>	<b>36.5</b>	<b>8.6</b>	<b>26.4</b>	<b>0.10</b>
<i>Adjusted Margin</i>	<i>24.0 %</i>	<i>17.0 %</i>	—	—	—

For the nine months ended September 30, 2021	(Amounts in € millions, except as indicated otherwise)				Diluted EPS
	EBITDA	Operating Profit	Income Taxes	Net Profit	
Reported	160.1	118.8	22.3	89.7	0.36
Adjusting items:					
Restructuring and related charges <sup>(2)</sup>	1.2	1.2	0.3	0.9	0.00
Incentive Plans Settlement <sup>(3)</sup>	(9.9)	(9.9)	(4.8)	(5.1)	(0.02)
IPO costs <sup>(4)</sup>	0.7	0.7	0.2	0.5	0.00
Out-of-cycle bonus to personnel <sup>(5)</sup>	6.7	6.7	1.8	4.9	0.02
Foreign exchange loss for derivatives on IPO proceeds <sup>(6)</sup>	—	—	1.0	3.3	0.01
Start-up costs U.S. plant <sup>(1)</sup>	0.6	0.6	0.2	0.5	0.00
Patent Box <sup>(7)</sup>	—	—	7.1	(7.1)	(0.03)
<b>Adjusted</b>	<b>159.4</b>	<b>118.1</b>	<b>28.2</b>	<b>87.5</b>	<b>0.35</b>
<i>Adjusted Margin</i>	<i>26.1 %</i>	<i>19.3 %</i>	—	—	—

<sup>(1)</sup> During the three and the nine months ended September 30, 2022, the Group recorded €1.6 million and €4.6 million, respectively, of start-up costs for the new plant in Fishers, Indiana, United States, in Zhangjiagang, China, and in Latina, Italy. During the first three quarters of 2021, the Group recorded €0.6 million of start-up costs to further the construction of the new plant in Fishers, Indiana, United States.

<sup>(2)</sup> During the three and the nine months ended September 30, 2021, the Group recorded €0.2 million and €1.2 million, respectively, in restructuring and related charges for the consolidation of Balda plants in the U.S.

<sup>(3)</sup> During the nine months ended September 30, 2021, the Group recorded €9.9 million, within general and administrative expenses, as an accrual reversal related to the early termination of incentive plans aimed at a limited number of key managers. The three months ended September 30, 2021 are not affected by this non-recurring item.

<sup>(4)</sup> During the three and the nine months ended September 30, 2021, the Group recorded €0.7 million, within general and administrative expenses, relating to the listing of Stevanato Group's ordinary shares on the NYSE.

<sup>(5)</sup> During the three and the nine months ended September 30, 2021, the Group granted a €6.7 million discretionary, out-of-cycle bonus to employees.

<sup>(6)</sup> During the three and the nine months ended September 30, 2021, the Group recorded €3.3 million, as foreign exchange loss for derivatives on IPO proceeds.

<sup>(7)</sup> During the nine months ended September 30, 2021, the Group reached an agreement with the Italian Tax agency regarding the so-called "Patent box regime", resulting in a retroactive tax saving for the financial years 2016-2020 amounting to €5.5 million based on our initial estimates.

## CAPEX

Capital Expenditure, or CAPEX, is the sum of investment amounts in tangible fixed assets and intangible assets during the period (excluding right-of-use assets recognized during the period in accordance with IFRS 16 Leases). These investment activities consist of acquisitions of property, plant and equipment and intangible assets. The following table sets forth the CAPEX for the three and the nine months ended September 30, 2022, and 2021:

	(Amounts in € millions, except as indicated otherwise)							
	For the three months ended September 30,		Change		For the nine months ended September 30,		Change	
	2022	2021	€		2022	2021	€	
Addition to Property, plant and equipment	68.4	24.2	44.2		194.6	67.5	127.1	
Addition to Intangible Assets	2.7	1.3	1.4		7.8	3.4	4.4	
<b>CAPEX</b>	<b>71.1</b>	<b>25.5</b>	<b>45.6</b>		<b>202.4</b>	<b>70.9</b>	<b>131.5</b>	

See Note 17 “Intangible Assets” and Note 18 “Property, plant and equipment” to the Interim Condensed Consolidated Financial Statements for additional details.

For further information on Capital Expenditure on a paid-out cash basis see “Liquidity and Capital Resources Capital Expenditure” below.

#### Free Cash Flow

Free Cash Flow is defined as cash flows from operating activities excluding interests paid and received, less investments in property, plant and equipment and intangible assets on a cash basis.

The following table sets forth the calculation of Free Cash Flow for the three and the nine months ended September 30, 2022, and 2021:

	(Amounts in € millions, except as indicated otherwise)							
	For the three months ended September 30,		Change		For the nine months ended September 30,		Change	
	2022	2021	€		2022	2021	€	
Cash flow from operating activities	(3.8)	17.9	(21.7)		43.6	77.9	(34.3)	
Interest paid	0.7	0.9	(0.2)		2.5	3.1	(0.6)	
Interest received	(0.1)	(0.1)	—		(0.5)	(0.5)	—	
Purchase of property, plant and equipment	(40.4)	(27.3)	(13.1)		(167.1)	(71.4)	(95.7)	
Proceeds from sale of property plant and equipment	—	—	—		0.5	—	0.5	
Purchase of intangible assets	(2.7)	(1.3)	(1.4)		(7.8)	(3.4)	(4.4)	
<b>Free Cash Flow</b>	<b>(46.3)</b>	<b>(9.9)</b>	<b>(36.4)</b>		<b>(128.8)</b>	<b>5.8</b>	<b>(134.6)</b>	

For further information on cash flow see “Liquidity and Capital Resources Operating and Investing Activities” below.

#### Net Cash/ (Debt)

The following table sets forth the calculation of Net Cash/ (Debt), which is a metric used by the management to analyze the financial stability of our business. Net Cash/ (Debt) is calculated by adding up current and non-current financial liabilities and subtracting the current financial assets, non-current financial receivables and cash and cash equivalent.

	(Amounts in € millions, except as indicated otherwise)	
	At September 30, 2022	At December 31, 2021
Non-current financial liabilities	(170.8 )	(202.3 )
Current financial liabilities	(72.9 )	(46.2 )
Other current financial assets	33.4	27.2
Cash and cash equivalents	259.9	411.0
<b>Net Cash</b>	<b>49.6</b>	<b>189.8</b>

#### *Capital Employed*

The following table sets forth the reclassified consolidated statements of financial position which is presented to aid management in their analysis of the Capital Employed to generate profits. Capital Employed is determined as the sum of non-current assets, net working capital, which is the difference between current assets and current liabilities, net of non-current liabilities.

	(Amounts in € millions, except as indicated otherwise)	
	At September 30, 2022	At December 31, 2021
- Goodwill and Other intangible assets	81.7	79.2
- Right of Use assets	21.0	22.7
- Property, plant and equipment	570.2	392.7
- Financial assets - investments FVTPL	1.1	1.1
- Other non-current financial assets	0.9	1.3
- Deferred tax assets	65.7	55.9
<b>Non-current assets</b>	<b>740.6</b>	<b>552.9</b>
- Inventories	218.1	148.9
- Contract assets	91.7	62.1
- Trade receivables	204.2	165.3
- Trade payables	(203.1 )	(164.8 )
- Advances from customers	(26.8 )	(23.6 )
- Contract liabilities	(23.1 )	(18.8 )
<b>Trade working capital</b>	<b>261.0</b>	<b>169.1</b>
- Tax receivables and Other receivables	80.3	51.4
- Tax payables and Other liabilities	(117.9 )	(85.3 )
<b>Net working capital</b>	<b>223.4</b>	<b>135.3</b>
- Deferred tax liabilities	(21.7 )	(19.1 )
- Employees benefits	(8.0 )	(11.9 )
- Provisions	(4.9 )	(3.5 )
- Other non-current liabilities	(16.0 )	(1.8 )
<b>Total non-current liabilities and provisions</b>	<b>(50.6 )</b>	<b>(36.3 )</b>
<b>Capital Employed</b>	<b>913.5</b>	<b>651.9</b>
<b>Net Cash</b>	<b>49.6</b>	<b>189.8</b>
<b>Equity</b>	<b>(963.1 )</b>	<b>(841.7 )</b>
<b>Total Equity and Net Cash</b>	<b>(913.5 )</b>	<b>(651.9 )</b>

## Backlog

Our backlog represents, as of a point in time, estimated future revenue for work not yet completed under (i) specific purchase orders, with regards to our Biopharmaceutical and Diagnostic Solutions segment; and (ii) certain one-off agreements, with regards to our Engineering segment. We recognize direct revenue over the life of the contract based on our performance of services under the contract. Contracts may be terminated or delayed by our customers or regulatory authorities for reasons beyond our control. To the extent projects are delayed, the timing of our revenue could be affected. In the event a customer terminates a contract, we are generally entitled to be paid for services rendered through the termination date and for services provided in winding down the project. However, we are only rarely entitled to receive the full amount of direct revenue reflected in our backlog in the event of a contract termination. The duration of the projects in our backlog, and the related revenue recognition, ranges from several months to a couple of years. For orders that are placed inside a contractual firm period, we generally have a contractual right to payment in the event of cancellation. Fluctuations in our reported backlog levels also result from the timing and order pattern of our customers who often seek to manage their level of inventory on hand.

Because of customer ordering patterns, our backlog reported for certain periods may fluctuate and may not be indicative of future results. A number of factors may affect backlog and the direct revenue generated from our backlog, including: (a) the size, complexity and duration of projects; and (b) the cancellation or delay of projects.

Our backlog as of September 30, 2022, was approximately €1,011.0 million, compared to approximately €880.0 million as of December 31, 2021, and of approximately €834.3 million as of September 30, 2021.

For the third quarter of 2022, new order intake totaled €246.9 million compared to €309.9 million for the third quarter of 2021. The year-over-year decrease was due to a significant drop in Covid-19 orders as the pandemic wanes. Excluding Covid-19, new order intake increased by approximately 6% in the third quarter of 2022 compared to last year, demonstrating that the underlying demand trends remain strong. During the nine months ended September 30, 2022, we had a new order intake of approximately €823.3 million compared to approximately €838.9 million for the nine months ended September 30, 2021. The Group anticipates that there may be fluctuations quarter to quarter in order intake and backlog.

Although an increase in backlog will generally result in an increase in future direct revenue to be recognized over time (depending on future contract modifications, contract cancellations and other adjustments), an increase in backlog at a particular point in time does not necessarily correspond to an increase in direct revenue during a particular period. The timing and extent to which backlog will result in direct revenue depends on many factors, including the timing of commencement of work, the rate at which we perform services, scope changes, cancellations, delays, receipt of regulatory approvals and the nature, duration, size, complexity and phase of the studies. In addition, delayed projects remain in backlog until they are cancelled. As a result of these factors, our backlog is not necessarily a reliable indicator of future direct revenue, and we might not realize all or any part of the direct revenue from the authorizations in backlog as of any point in time.

## Components of Our Results of Operations

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

Results discussed in this section of the quarterly report are consolidated according to IFRS accounting principles and therefore do not include Company's inter-segment items other than where we specifically note otherwise.

### Revenue and Segment Reporting

Our revenue is divided into two main segments:

(i) **Biopharmaceutical and Diagnostic Solutions:** which includes the products, processes and services developed and provided connection with the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. This segment is split into two sub-categories:

- high-value solutions; and
- other containment and delivery solutions.

(ii) **Engineering:** which includes the equipment and technologies developed and provided to support the end-to-end biopharmaceutical and diagnostic manufacturing processes (machinery for assembly, visual inspection, packaging and



serialization and glass converting). We believe operating in this segment differentiates us from our competitors, and enables us to provide integrated end-to-end solutions, reduce time to market and improve the quality of our products.

Revenue recognized in the three months ended September 30, 2022, and 2021, amounted to €245.3 million and €214.5 million, respectively. Revenue recognized in the nine months ended September 30, 2022, and 2021, amounted to €691.6 million and €611.3 million, respectively.

In the nine months ended September 30, 2022, and 2021, we generated 82% and 83% of total sales from our Biopharmaceutical and Diagnostic Solutions segment, respectively, and 18% and 17% from our Engineering segment, respectively.

The following tables set forth the results of our business operations for the aforementioned segments, which include inter-segment items, and the reconciliation with the consolidated figures, for the three and the nine months ended September 30, 2022, and 2021.

Revenue for each segment is divided into "External Customers", representing revenue from third parties sales, and "Inter-Segment", representing the revenue from the sales generated from the transactions with other segments, and is then reconciled with the Consolidated Revenue which does not include inter-segment items.

Gross Profit margin is calculated by dividing Gross Profit for a period by total revenue for the same period. Operating Profit margin is calculated by dividing Operating Profit for a period by total revenue for the same period. Gross Profit margin and Operating profit margin for both Biopharmaceutical and Diagnostic Solutions segment and Engineering segment include the effect of inter-segment transactions.

	For the three months ended September 30, 2022			
	Biopharmaceutical and Diagnostic Solutions	Engineering	Adjustments, eliminations and unallocated items	Consolidated
External Customers	207.1	38.2	—	245.3
Inter-Segment	0.4	32.5	(32.9)	—
<b>Revenue</b>	<b>207.5</b>	<b>70.7</b>	<b>(32.9)</b>	<b>245.3</b>
<b>Gross Profit</b>	<b>67.8</b>	<b>15.2</b>	<b>(5.5)</b>	<b>77.5</b>
<b>Gross Profit Margin</b>	<b>32.7 %</b>	<b>21.5 %</b>		<b>31.6 %</b>
<b>Operating Profit</b>	<b>47.3</b>	<b>9.9</b>	<b>(9.7)</b>	<b>47.5</b>
<b>Operating Profit Margin</b>	<b>22.8 %</b>	<b>14.0 %</b>		<b>19.4 %</b>

  

	For the nine months ended September 30, 2022			
	Biopharmaceutical and Diagnostic Solutions	Engineering	Adjustments, eliminations and unallocated items	Consolidated
External Customers	568.1	123.4	—	691.6
Inter-Segment	1.0	83.7	(84.7)	—
<b>Revenue</b>	<b>569.1</b>	<b>207.1</b>	<b>(84.7)</b>	<b>691.6</b>
<b>Gross Profit</b>	<b>188.2</b>	<b>45.1</b>	<b>(13.7)</b>	<b>219.6</b>
<b>Gross Profit Margin</b>	<b>33.1 %</b>	<b>21.8 %</b>		<b>31.8 %</b>
<b>Operating Profit</b>	<b>127.6</b>	<b>30.0</b>	<b>(28.3)</b>	<b>129.3</b>
<b>Operating Profit Margin</b>	<b>22.4 %</b>	<b>14.5 %</b>		<b>18.7 %</b>

	For the three months ended September 30, 2021			Consolidated
	Biopharmaceutical and Diagnostic Solutions	Engineering	Adjustments, eliminations and unallocated items	
External Customers	172.8	41.8	—	214.5
Inter-Segment	0.3	17.7	(18.0)	—
<b>Revenue</b>	<b>173.1</b>	<b>59.5</b>	<b>(18.0)</b>	<b>214.5</b>
<b>Gross Profit</b>	<b>53.9</b>	<b>9.1</b>	<b>0.2</b>	<b>63.3</b>
<b>Gross Profit Margin</b>	<b>31.2 %</b>	<b>15.4 %</b>		<b>29.5 %</b>
<b>Operating Profit</b>	<b>31.3</b>	<b>4.2</b>	<b>(7.3)</b>	<b>28.2</b>
<b>Operating Profit Margin</b>	<b>18.1 %</b>	<b>7.1 %</b>		<b>13.1 %</b>

	For the nine months ended September 30, 2021			Consolidated
	Biopharmaceutical and Diagnostic Solutions	Engineering	Adjustments, eliminations and unallocated items	
External Customers	508.2	103.2	—	611.3
Inter-Segment	0.8	39.3	(40.1)	—
<b>Revenue</b>	<b>509.0</b>	<b>142.5</b>	<b>(40.1)</b>	<b>611.3</b>
<b>Gross Profit</b>	<b>168.8</b>	<b>25.6</b>	<b>(2.0)</b>	<b>192.4</b>
<b>Gross Profit Margin</b>	<b>33.2 %</b>	<b>18.0 %</b>		<b>31.5 %</b>
<b>Operating Profit</b>	<b>111.2</b>	<b>12.0</b>	<b>(4.4)</b>	<b>118.8</b>
<b>Operating Profit Margin</b>	<b>21.8 %</b>	<b>8.4 %</b>		<b>19.4 %</b>

## Results of Operations

Three and nine months ended September 30, 2022 versus three and nine months ended September 30, 2021

The following table set forth our results of operations for the three months ended September 30, 2022, and 2021.

	(Amounts in € millions, except as indicated otherwise)					
	For the three months ended				Change	
	2022	% of revenue	September 30, 2021	% of revenue	€	%
Revenue	245.3	100.0 %	214.5	100.0 %	30.8	14.4 %
Costs of sales	167.7	68.4 %	151.3	70.5 %	16.4	10.8 %
<b>Gross Profit</b>	<b>77.5</b>	<b>31.6 %</b>	<b>63.3</b>	<b>29.5 %</b>	<b>14.2</b>	<b>22.4 %</b>
Other operating Income	3.4	1.4 %	1.7	0.8 %	1.7	100.0 %
Selling and Marketing Expenses	5.9	2.4 %	4.7	2.2 %	1.2	25.5 %
Research and Development Expenses	7.6	3.1 %	7.4	3.4 %	0.2	2.7 %
General and Administrative Expenses	20.0	8.2 %	24.7	11.5 %	(4.7)	-19.0 %
<b>Operating Profit</b>	<b>47.5</b>	<b>19.4 %</b>	<b>28.2</b>	<b>13.2 %</b>	<b>19.3</b>	<b>68.4 %</b>
Finance Income	6.7	2.7 %	2.1	1.0 %	4.6	219.0 %
Finance Expense	8.3	3.4 %	8.0	3.7 %	0.3	3.8 %
Share of Profit of an Associate	—	0.0 %	0.2	0.1 %	(0.2)	-100.0 %
<b>Profit Before Tax</b>	<b>46.0</b>	<b>18.8 %</b>	<b>22.4</b>	<b>10.4 %</b>	<b>23.6</b>	<b>105.4 %</b>
Income Taxes	9.8	4.0 %	3.8	1.8 %	6.0	157.9 %
<b>Net Profit</b>	<b>36.3</b>	<b>14.8 %</b>	<b>18.6</b>	<b>8.7 %</b>	<b>17.7</b>	<b>95.2 %</b>

The following table set forth our results of operations for the nine months ended September 30, 2022, and 2021.

	(Amounts in € millions, except as indicated otherwise)							
	For the nine months ended				Change		Change	
	September 30,		September 30,		€		%	
	2022	% of revenue	2021	% of revenue				
Revenue	691.6	100.0 %	611.3	100.0 %	80.3		13.1 %	
Costs of sales	472.0	68.2 %	419.0	68.5 %	53.0		12.6 %	
<b>Gross Profit</b>	<b>219.6</b>	<b>31.8 %</b>	<b>192.4</b>	<b>31.5 %</b>	<b>27.2</b>		<b>14.1 %</b>	
Other operating Income	12.1	1.7 %	7.2	1.2 %	4.9		68.1 %	
Selling and Marketing Expenses	17.8	2.6 %	16.0	2.6 %	1.8		11.3 %	
Research and Development Expenses	23.8	3.4 %	20.1	3.3 %	3.7		18.4 %	
General and Administrative Expenses	60.8	8.8 %	44.7	7.3 %	16.1		36.0 %	
<b>Operating Profit</b>	<b>129.3</b>	<b>18.7 %</b>	<b>118.8</b>	<b>19.4 %</b>	<b>10.5</b>		<b>8.8 %</b>	
Finance Income	17.2	2.5 %	6.4	1.0 %	10.8		168.8 %	
Finance Expense	22.7	3.3 %	13.7	2.2 %	9.0		65.7 %	
Share of Profit of an Associate	—	0.0 %	0.5	0.1 %	(0.5)		-100.0 %	
<b>Profit Before Tax</b>	<b>123.8</b>	<b>17.9 %</b>	<b>112.0</b>	<b>18.3 %</b>	<b>11.8</b>		<b>10.5 %</b>	
Income Taxes	29.1	4.2 %	22.3	3.7 %	6.8		30.5 %	
<b>Net Profit</b>	<b>94.7</b>	<b>13.7 %</b>	<b>89.7</b>	<b>14.7 %</b>	<b>5.0</b>		<b>5.6 %</b>	

#### Revenue

Revenue increased by €30.7 million, or 14.3%, to €245.3 million for the three months ended September 30, 2022, compared to €214.5 million for the three months ended September 30, 2021, driven by sales growth in our Biopharmaceutical and Diagnostic Solutions segment and favorable currency translation. For the three months ended September 30, 2022, we estimate that COVID-19 related revenue represented approximately 13.3% of our total revenue compared to 15.5% for the three months ended September 30, 2021. Revenue growth on constant currency basis was 10.6% for the nine months ended September 30, 2022.

Revenue increased by €80.2 million, or 13.1%, to €691.6 million for the nine months ended September 30, 2022, compared to €611.3 million for the nine months ended September 30, 2021, driven by sales growth in both our Biopharmaceutical and Diagnostic Solutions segment and our Engineering segment, and favorable currency translation. Revenue for the nine months ended September 30, 2021 included a €5.5 million benefit in our Biopharmaceutical and Diagnostic Solutions segment related to a licensing agreement which benefitted margins, net profit and earnings in the first quarter of 2021. For the nine months ended September 30, 2022, we estimate that COVID-19 related revenue represented approximately 11.1% of our total revenue compared to approximately 14.8% for the nine months ended September 30, 2021. Revenue growth on constant currency basis was 9.9% for the nine months ended September 30, 2022.

#### Biopharmaceutical and Diagnostic Solutions

Revenue generated by the Biopharmaceutical and Diagnostic Solutions segment increased by €34.3 million, or 19.9% (approximately 15.2% on a constant currency basis), to €207.1 million for the three months ended September 30, 2022, compared to €172.8 million in the three months ended September 30, 2021. All growth was organic and driven by growth in our drug containment products. Revenue generated from our premium priced, high-value solutions increased by €26.0 million, or 53.8%, to €74.4 million for the three months ended September 30, 2022, compared to €48.4 million for the three months ended September 30, 2021. Revenue generated by other containment and delivery solutions increased by €8.3 million, or 6.7%, to €132.7 million compared to €124.4 million for the three months ended September 30, 2021.

On a constant currency basis, revenue generated from high-value solutions increased by €23.7 million, or 49.9% to €72.0 million for the three months ended September 30, 2022, compared to €48.4 million, for the three months ended September 30, 2021, and revenue generated by other containment and delivery solutions increased by €2.6 million, or 2.1%, to €127.0 million for the three months ended September 30, 2022, compared to €124.4 million for the three months ended September 30, 2021.

For the three months ended September 30, 2022, we estimate that approximately 15.7% of segment revenue is related to COVID-19 compared to, approximately 19.2%, of segment revenue estimated for the three months ended September 30, 2021.

Revenue generated by the Biopharmaceutical and Diagnostic Solutions segment increased by €59.9 million, or 11.8%, to €568.1 million for the nine months ended September 30, 2022, compared to €508.2 million in the nine months ended September 30, 2021.

Revenue growth was driven by an increase in revenue of our premium priced high-value solutions, which grew by €64.6 million, or 45.7%, to €206.0 million for the nine months ended September 30, 2022, compared to €141.4 million for the nine months ended September 30, 2021, reflecting our strategic shift towards a higher proportion of high-value solutions, such as EZ-Fill<sup>®</sup> vials and cartridges, high-value syringes, Alba<sup>®</sup>, Nexa<sup>®</sup>, Drug Delivery Systems, analytical services and molecular diagnostic plastic parts. Revenue from our other containment and delivery solutions decreased by €4.6 million, or 1.3%, to €362.1 million for the nine months ended September 30, 2022, compared to €366.7 million for the nine months ended September 30, 2021, mainly due to the aforementioned €5.5 million benefit and shift to high-value solutions products.

On a constant currency basis, revenue generated from high-value solutions increased by €58.2 million, or 41.1%, to €199.6 million in the nine months ended September 30, 2022, compared to €141.4 million in the nine months ended September 30, 2021, while revenue generated by other containment and delivery solutions decreased by €18.0 million, or 4.9%, to €348.7 million in the nine months ended September 30, 2022, compared to €366.7 million in the nine months ended September 30, 2021.

For the nine months ended September 30, 2022, we estimate that approximately €76.7 million, or 13.5%, of segment revenue is related to COVID-19 compared to approximately €90.4 million, or 17.8%, of segment revenue estimated for the nine months ended September 30, 2021.

#### *Engineering*

Revenue generated by the Engineering segment, decreased by €3.6 million, or 8.6%, to €38.2 million for the three months ended September 30, 2022, compared to €41.8 million for the three months ended September 30, 2021. Revenue decreased principally due to the timing and progression of projects in certain business lines and in line with Company expectations.

Revenue generated by the Engineering segment, increased by €20.3 million, or 19.6%, to €123.4 million for the nine months ended September 30, 2022, compared to €103.2 million for the nine months ended September 30, 2021. Revenue growth was driven by higher sales in all business lines, including visual inspection systems, assembly and packaging machines, glass converting machines, and also after sales activities.

We do not consider any of the revenue in our Engineering segment to be attributable to COVID-19 since: (i) we cannot accurately determine the end use of our products; and (ii) most of our products have life cycles of 10 years or more and, therefore, bear a reasonably likely chance of being used for purposes other than COVID-19 related.

#### *Revenue Breakdown by Region*

For the three months ended September 30, 2022, revenue in APAC region decreased by €10.3 million, or 31.2% to €22.8 million (which accounted for 9.3% of our total revenue for the three months ended September 30, 2022) compared to €33.2 million in the three months ended September 30, 2021. For the same period, revenue in North America increased by €13.3 million, or 28.4% to €60.2 million (which accounted for 24.5% of our total revenue for the three months ended September 30, 2022) compared to €46.8 million in the three months ended September 30, 2021, while in EMEA and South America revenue increased by €25.6 million, or 20.1% to €152.7 million (which accounted for 62.3% of our total revenue for the three months ended September 30, 2022) compared to €127.2 million in the three months ended September 30, 2021, and by €2.2 million, or 29.9%, to €9.5 million (which accounted for 3.9% of our total revenue for the three months ended September 30, 2022), respectively.

For the nine months ended September 30, 2022, revenue in APAC region decreased by €3.0 million, or 3.9%, to €74.3 million in the APAC region (which accounted for approximately 10.7% of our total revenue for the nine months ended September 30, 2022) compared to €77.3 million in the nine months ended September 30, 2021, by €50.9 million, or 14.0%, to €414.0 million in Europe (which accounted for approximately 59.9% of our total revenue for the nine months ended September 30, 2022) compared to €363.1 million in the nine months ended September 30, 2021, and by €6.0 million, or 32.2%, to €24.6 million in South America (which accounted for approximately 3.6% of our total revenue for the nine months ended September 30, 2022) compared to €18.6 million in the nine months ended September 30, 2021. Revenue in North America (which accounted for approximately 25.8% of our total revenue for the nine months ended September 30, 2022) increased by €26.4 million, or 17.3% to €178.7 million compared to €152.3 million in the nine months ended September 30, 2021.

### **Cost of Sales**

Cost of sales increased by €16.5 million, or 10.9%, to €167.7 million for the three months ended September 30, 2022, compared to € 151.3 million for the three months ended September 30, 2021. The increase in cost of sales resulted from a general increase in the cost of materials and components, and direct and indirect personnel costs mainly to support the growth of our sales volumes.

Cost of sales was also negatively impacted by inflation in materials, a spike in utilities, and increased logistical costs.

Cost of sales increased by €53.0 million, or 12.7%, to €472.0 million for the nine months ended September 30, 2022, compared to €419.0 million for the nine months ended September 30, 2021, mainly due to the higher cost of materials, components and labor expenses related to the production and distribution of our goods and services. Cost of sales was also impacted by an increase in logistical costs and utilities, mainly due to the worldwide increase in natural gas and electricity rates.

Industrial depreciation and amortization increased due to the availability for use of the machinery installed in the previous months to increase the production capacity.

For the nine months ended September 30, 2022, cost of sales included €1.9 million of non-recurring start-up costs related to the new facilities in Indiana, U.S., in Zhangjiagang, China, and in Latina, Italy.

### **Gross Profit**

For the three months ended September 30, 2022, gross profit increased by €14.2 million, or 22.4%, to €77.5 million, compared to €63.3 million for the three months ended September 30, 2021. As a result, gross profit margin increased to 31.6% for the three months ended September 30, 2022, compared to 29.5% for the same period last year, mainly driven by higher sales of more accretive high-value solutions, increased profitability in our Engineering segment and favorable currency translation. This growth was impacted by an increase in inflationary costs, especially utilities and logistics which have been partially offset by price adjustments.

For the three months ended September 30, 2022, gross profit margin for the Biopharmaceutical and Diagnostic Solutions segment increased to 32.7% compared to 31.2% for the three months ended September 30, 2021, driven by a higher mix of more accretive high value solutions and favorable currency translation. This increase was partially offset by the aforementioned inflationary costs.

For the three months ended September 30, 2022, gross profit margin for the Engineering segment increased to 21.5% compared to 15.4% for the three months ended September 30, 2021. The increase was mainly driven by contributions from an increasing mix of more accretive business lines, as well as ongoing optimization efforts. The improved profitability has been reflected in all business lines.

For the nine months ended September 30, 2022, gross profit increased by €27.2 million, or 14.1%, to €219.6 million, compared to €192.4 million for the nine months ended September 30, 2021. As a result, gross profit margin increased to 31.8% for the nine months ended September 30, 2022, compared to 31.5% for the nine months ended September 30, 2021, which included a €5.5 million benefit related to a licensing agreement without the associated cost of sales. Excluding this benefit, gross profit margin for the nine months ended September 30, 2021, would have been 30.8%. The year-over-year increase in gross profit margin was driven by the strategic mix shift towards more accretive high value solutions, improved margin in the Engineering segment and, favorable currency translation. This was impacted by the unfavorable impact of a production slowdown due to COVID-19 in the first two months of the year and a rise in inflationary costs which have been partially offset by price adjustments.

For the nine months ended September 30, 2022, gross profit margin for the Biopharmaceutical and Diagnostic Solution segment was 33.1% compared to 33.2% for the nine months ended September 30, 2021, which included a €5.5 million benefit related to a licensing agreement without the associated cost of sales. Excluding this benefit gross profit margin for the nine months ended September 30, 2021 would have been 32.4%. As a result gross profit margin was driven by the continuing mix shift to high value solutions, partially offset by the unfavorable impact of a production slowdown due to COVID-19 in the first two months of the year and a rise in inflationary costs, which have been partially offset by price adjustments.

Engineering segment gross profit margin increased to 21.8% for the nine months ended September 30, 2022, compared to 18.0% for the nine months ended September 30, 2021. The increase was mainly driven by contributions from more accretive business lines, as well as ongoing business optimization efforts to improve operational efficiencies. Profitability has improved particularly as a result of our glass forming and pharma vision business.

### ***Other Operating Income***

Other operating income, which includes all revenue from customers not derived from the sale of our products, services and solutions such as revenue from feasibility studies, design, development and industrialization of new products, orders amendment fees, government grants, increased by €4.9 million, or 68%, to €12.1 million for the nine months ended September 30, 2022, compared to €7.2 million for the nine months ended September 30, 2021. Other operating income represents a minor part of our income and its amount varies yearly depending on the specific business agreements in place.

For the three months ended September 30, 2022, other income increased by €1.7 million, or 100%, to €3.4 million, compared to €1.7 million for the three months ended September 30, 2021, and included approximately €1.6 million related to a contract modification and also includes residual fees related to a previous contract modification disclosed in the second quarter of 2022. The modification was made to accommodate a decrease in COVID-19 related orders.

### ***Selling and Marketing Expenses***

Selling and marketing expenses increased by €1.2 million, or 25.5%, to €5.9 million for the three months ended September 30, 2022, compared to €4.7 million for the three months ended September 30, 2021. The increase is mainly related to business development costs for events and travel as in-person industry events are returning to pre-pandemic levels, partially compensated by €0.4 million lower accrual for doubtful debts. Further deviation compared with three months ended September 30, 2021 is due to a provision for sundry risk related to personnel tax qualification of accruals to pension funds accrued in general and administrative expenses for the three months ended June 30, 2022.

Selling and marketing expenses increased by €1.8 million, or 11.3%, to €17.8 million for the nine months ended September 30, 2022, compared to €16.0 million for the nine months ended September 30, 2021. These expenses are mainly related to business development and events costs, travel expenses and other marketing strategic consultancies. These expenses also include depreciation respectively for €0.5 million and for €0.6 million for the nine months ended September 30, 2022, and 2021. For the nine months ended September 30, 2022, selling and marketing expenses included a release of the provision for bad and doubtful debts of €0.1 million (for the nine months ended September 30, 2021 the accrual for bad and doubtful debts provision amounted to €0.7 million).

### ***Research and Development Expenses***

Research and development expenses increased by €0.2 million, or 2.7%, to €7.6 million for the three months ended September 30, 2022, compared to €7.4 million for the three months ended September 30, 2021. The increase is mainly related to higher personnel costs due to new hires to sustain and progress the strategic R&D activities launched at the Group level.

Research and development expenses increased by €3.7 million, or 18.4%, to €23.8 million for the nine months ended September 30, 2022, compared to €20.1 million for the nine months ended September 30, 2021. Such expenses include costs for research and development activities to support the innovation of our product range and include amortization and depreciation for €2.6 million for the nine months ended September 30, 2022 (€2.5 million for the nine months ended September 30, 2021). The increase in research and development expenses reflects our investments in premium primary packaging and drug delivery systems to accelerate our market-leading position, strengthen our IP, and develop new technologies to advance patient care.

### ***General and Administrative Expenses***

General and administrative expenses decreased by €4.8 million, or 19.4%, to €19.9 million for the three months ended September 30, 2022, compared to €24.7 million in the three months ended September 30, 2021, which included a €6.7 million discretionary, out-of-cycle bonus to employees. Without this effect, the three months ended September 30, 2022 recorded an increase in labor costs to support the growth of the business and strengthen our regional organizational structure as we progress of our global expansion, compared to the three months ended September 30, 2021. Moreover, the three months ended September 30, 2022 included higher costs associated with our status as a public company, such as insurance and other organizational structure costs.

General and administrative expenses increased by €16.1 million, or 36.0%, to €60.8 million for the nine months ended September 30, 2022, compared to €44.7 million in the nine months ended September 30, 2021. These expenses mainly comprise personnel

expenses for management of the company, consultancy costs, rentals, as well as depreciation and amortization of €5.1 million (compared to €4.4 million for the nine months ended September 30, 2021), of which amortization of fair value adjustments from purchase price allocations amounted to €0.8 million (€0.8 million for the nine months ended September 30, 2021). The year-over-year increase in general and administrative expenses was mainly due to higher labor costs for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 which included a non-recurring accrual reversal amounting to €9.9 million related to cash settled awards under incentive plans 2012-2021 and 2018-2022 which were terminated in favor of the new stock grant plan 2021-2027 partially offset by a €6.7 million discretionary, out-of-cycle bonus to employees. In addition, the increase was also attributable to: (i) higher costs associated with our status as a public company, such as insurance and other organizational structure costs, impacted general and administrative expenses; (ii) non-recurring, start-up costs for the new EZ-fill® hub in Fishers, Indiana, United States; and (iii) higher IT costs.

### ***Operating Profit***

As a result of the foregoing, operating profit increased by €19.3 million, or 68.4%, to €47.5 million for the three months ended September 30, 2022, compared to €28.2 million for the three months ended September 30, 2021. As a result, operating profit margin for the three months ended September 30, 2022, increased to 19.4% compared to 13.2% for the three months ended September 30, 2021, driven by an increasing mix of more accretive high value solutions, increased profitability in our Engineering segment, an increase in other income, lower G&A costs, and favorable currency translation. This was impacted by an increase in inflationary costs which have been partially offset by price adjustments.

For the three months ended September 30, 2022, the operating profit margin for the Biopharmaceutical and Diagnostic Solution segment was 22.8%, compared to 18.1% for the three months ended September 30, 2021. The increase is mainly driven by: (i) higher sales volumes; (ii) an increased mix of more accretive high-value solutions; (iii) higher Other Operating Income; and (iv) lower G&A costs.

For the three months ended September 30, 2022, Engineering operating profit margin was 14.0%, compared to 7.1% for the three months ended September 30, 2021. The increase was mainly driven by better marginality and lower G&A expenses.

For the nine months ended September 30, 2022, operating profit increased by €10.9 million or 8.8%, to €129.3 million compared to €118.8 million for the same period last year. This resulted in operating profit margin of 18.7% for the nine months ended September 30, 2022 compared to 19.4% for same period last year, as the benefits due to the favorable mix shift to high value solutions and better marginality in the Engineering segment were more than offset by: (i) a production slowdown due to COVID-19; (ii) an increase in inflationary costs, that have been partially offset by price adjustments; (iii) the aforementioned €5.5 million benefit from the licensing agreement recorded in the nine months ended September 30, 2021; (iv) the increase in selling and marketing expenses from an increase in industry events and promotional activities; (v) the increase in general and administrative expenses connected to being a publicly traded company; (vi) start-up costs accounted for in the nine months ended September 30, 2022; (vii) non-recurring accrual reversal amounting to €9.9 million for the nine months ended September 30, 2021, partially offset by a €6.7 million discretionary, out-of-cycle bonus to employees; and (viii) the increase in research and development expenses reflecting our investments in premium primary packaging and drug delivery systems.

For the nine months ended September 30, 2022, the operating profit margin for the Biopharmaceutical and Diagnostic Solution segment was 22.8%, compared to 21.8% for the nine months ended September 30, 2021. The increase in operating profit margin was primarily due to the aforementioned favorable mix shift to high value solutions and increase in other operating income partially offset by: (i) production slowdown due to COVID-19; (ii) an increase in inflationary costs, that have been partially offset by price adjustments; (iii) the aforementioned €5.5 million benefit from the licensing agreement recorded in the nine months ended September 30, 2021; (iv) the increase in selling and marketing expenses from an increase in industry events and promotional activities; (v) the increase in general and administrative expenses connected to being a publicly traded company; (vi) start-up costs accounted for in the nine months ended September 30, 2022; and (vii) the increase in research and development expenses reflecting our investments in premium primary packaging and drug delivery systems.

For the nine months ended September 30, 2022, Engineering operating profit margin was 14.0%, compared to 8.4% for the nine months ended September 30, 2021. The increase in operating profit margin was primarily due to contributions from more accretive business lines and after-sales activities, as well as ongoing optimization efforts that resulted in an increased absorption of SG&A expenses, and lower G&A costs.

### **Net Finance Expenses**

Finance expenses, net of finance income, decreased by €4.4 million to €1.5 million for the three months ended September 30, 2022, from €6.0 million, net expense, for the three months ended September 30, 2021, which included a non-recurring loss of €4.3 million related to a derivative financial instrument to reduce the risk of fluctuations in the EUR/USD exchange rate in relation to the IPO proceeds.

Finance expenses, net of finance income, decreased by €1.8 million (or 24.7%) to €5.5 million for the nine months ended September 30, 2022, from €7.3 million for the nine months ended September 30, 2021. Finance expense include bank interest on the Group's financial debt (recalculated using the amortized cost method) and interest on leases, recognized in accordance with IFRS 16-Leases.

### **Profit Before Tax**

Profit before taxes increased by €23.6 million, or 105.4%, to €46.0 million for the three months ended September 30, 2022, compared to €22.4 million for the three months ended September 30, 2021.

Profit before taxes increased by €11.8 million, or 10.5%, to €123.8 million for the nine months ended September 30, 2022, compared to €112.0 million for the nine months ended September 30, 2021.

### **Income Taxes**

Income taxes increased by €5.9 million or 155.3%, to €9.7 million for the three months ended September 30, 2022, compared to €3.8 million for the three months ended September 30, 2021. The increase resulted from a higher profit before taxes for the quarter.

Income taxes increased by €6.8 million, or 30.5%, to €29.1 million for the nine months ended September 30, 2022, compared to €22.3 million for the nine months ended September 30, 2021.

	For the three months ended September 30,		(Amounts in € millions)		For the nine months ended September 30,		Change €
	2022	2021	Change €		2022	2021	
<b>Income Tax Expenses reported in the statement of profit or loss</b>	9.7	3.8	5.9		29.1	22.3	6.8

The increase in income taxes was mainly due to a € 7.1 million non-recurring tax saving accrued for the nine months ended September 30, 2021, related to the so called "Patent Box regime", a tax exemption related to, inter alia, the use of intellectual property assets, which did not have any effects in the nine months ended September 30, 2022.

### **Net Profit**

Net profit increased by €17.7 million, or 95.2%, to €36.3 million (or €0.14 of Diluted EPS or €0.14 of Adjusted Diluted EPS) for the three months ended September 30, 2022, compared to €18.6 million (or €0.07 of Diluted EPS or €0.10 of Adjusted Diluted EPS) for the three months ended September 30, 2021.

Net profit increased by €5 million, or 5.6%, to €94.7 million (or €0.36 of Diluted EPS or €0.36 of Adjusted Diluted EPS) for the nine months ended September 30, 2022, compared to €89.7 million (or €0.36 of Diluted EPS or €0.35 of Adjusted Diluted EPS) for the nine months ended September 30, 2021.

### **Liquidity and Capital Resources**



We finance our operations mainly through cash generated by our operating activities and debt financing and, from the proceeds of our IPO in 2021. Our primary requirements for liquidity and capital are to finance capital expenditures, working capital (which is the difference of current assets and current liabilities—net of current financial assets, current financial liabilities, cash and cash equivalents), and general corporate purposes.

Our primary sources of liquidity include our cash and cash equivalents and medium and long-term loans from a number of financial institutions, as described below. As of September 30, 2022, we had cash and cash equivalents of €259.9 million (compared to €411.0 million as of December 31, 2021) and other current financial assets of €33.4 million (compared to €27.2 million as of December 31, 2021). Our cash and cash equivalents primarily consist of cash at bank and highly liquid investments, such as short-term deposits, which are unrestricted from withdrawal or use, or which have original maturities of three months or less when purchased. We believe that our total available liquidity (defined as cash and cash equivalents, including part of the proceeds received at completion of our IPO, plus undrawn committed credit lines and marketable securities), in addition to funds that will be generated from operating activities, will enable us to satisfy the requirements of our investing activities and working capital needs for the next 12 months and ensure an appropriate level of operating and strategic flexibility.

Our total current liabilities were €443.7 million as of September 30, 2022 (compared to €338.6 million as of December 31, 2021), which primarily includes €203.1 million trade payables, €23.1 million contract liabilities, €26.8 million advances from customers, €72.9 million financial liabilities, €43.1 million tax payables, €5.6 million lease liabilities and €69.2 million other liabilities mainly relating to payables to personnel and social security institutions as well as allowance for future expected customer returns.

#### ***Financing activities***

We employ a disciplined approach in managing our working capital and balance sheet to support our business and operations.

#### **Capital Expenditures**

During the nine months ended September 30, 2022, capital expenditures for growth and capacity expansion were €180 million, which included: (i) €82.8 million for new production lines in Italy, including the new EZ-Fill® plant in Latina (of which €78 million is tied to our high value EZ-Fill® products); (ii) €87 million for new production lines and related building expansion in other plants, particularly in the U.S. and China facilities; (iii) €3.1 million for new machinery for high precision plastic injection molding and assembly for container in vitro diagnostic solutions; and (iv) €7.1 million for molds.

In the United States, we have completed the foundation work on our new facility and started construction of the building. We currently remain on track for starting commercial operations in late 2023 or early 2024. In Italy, we are making strong progress on our capacity expansion efforts. Construction is nearly completed on our new building in Piombino Dese. In addition, two of three planned new lines for 2022 are operational - including one EZ-fill® syringe line, and one line dedicated to premium Alba syringes. We expect to operationalize another EZ-fill® syringe line by the end of 2022. In China, we are nearing the end of the design phase and continue to anticipate revenue generation in the back half of 2024.

Capital expenditures for maintenance, increasing quality, improving our IT systems, improving efficiency of our production processes and improving safety of our plants and production sites amounted to €16.1 million, while for research and development, including laboratory equipment, molds and other related equipment, amounted to €6.3 million. We intend to devote approximately the same portion of capital expenditures to growth and capacity expansion in future years.

For fiscal year 2022, we anticipate capital expenditures will range between 30% and 35% of sales, comprising three main categories: 1) approximately 83% relates to growth platforms to fund capacity expansions primarily in high value solutions the U.S., China, and Italy; 2) approximately 5% for investment in research and development for glass primary packaging products and the ongoing advancement of drug delivery devices to maintain and accelerate our market leading position; and 3) approximately 15% to fund other investment areas such as innovation in operating efficiencies and quality, IT, maintenance, and safety.

#### **Cash Flow**

The following table presents the summary consolidated cash flow information for the periods presented.

	(Amounts in € millions, except as indicated otherwise)							
	For the three months ended September 30,		Change		For the nine months ended September 30,		Change	
	2022	2021	€		2022	2021	€	
Cash flows from operating activities	(3.8)	17.9	(21.7)		43.6	77.9	(34.3)	
Cash flows used in investing activities	(43.2)	(28.6)	(14.6)		(174.1)	(75.3)	(98.8)	
Cash flows from / (used in) financing activities	(9.9)	337.1	(347.0)		(25.9)	307.3	(333.2)	
<b>Net change in cash and cash equivalents</b>	<b>(57.0)</b>	<b>326.4</b>	<b>(383.4)</b>		<b>(156.5)</b>	<b>309.8</b>	<b>(466.3)</b>	

#### *Cash generated from / used in operating activities*

Net cash used in operating activities was €3.8 million for the three months ended September 30, 2022, (compared to cash generation of €17.9 million for the three months ended September 30, 2021). For the three months ended September 30, 2022, the EBITDA generation of €64.2 million was offset by €43.6 million of cash absorbed from the net change in working capital, which resulted from the growth of our business, and by €20.4 million in income tax paid and €4.0 million from other non-cash expenses.

Net cash generated from operating activities was €43.6 million for the nine months ended September 30, 2022 (compared to €77.9 million for the nine months ended September 30, 2021). For the nine months ended September 30, 2022, the EBITDA generation of €177.1 million was partially offset by €104.4 million of cash absorbed from the net change in working capital, which resulted from the growth of our business, and by €23.5 million in income tax paid.

#### *Cash used in investing activities*

Net cash used in investing activities was €43.2 million for the three months ended September 30, 2022 (compared to €28.6 million cash used in investing activities for the three months ended September 30, 2021), consisting mainly of the purchase of property and equipment to increase our production capacity for both our EZ-Fill® product portfolio and our bulk business. We also invested in R&D and in strengthening the security of our IT systems.

Net cash used in investing activities was €174.1 million for the nine months ended September 30, 2022 (compared to €75.3 million cash used in investing activities for the nine months ended September 30, 2021), consisting mainly of the purchase of property and equipment to increase our production capacity for both our EZ-Fill® product portfolio and our bulk business. We also invested in R&D and in strengthening the security of our IT systems.

#### *Cash generated from / used in financing activities*

Net cash flows used in financing activities was €9.9 million for the three months ended September 30, 2022 (compared to €337.1 million generated from financing activities for the three months ended September 30, 2021). For the three months ended September 30, 2022, loan repayments and the payment of the principal portion of lease liabilities amounted to €1.6 million and to €1.6 million, respectively. Dividends distributed amounted to €13.5 million and €6.9 million related to new borrowings.

Net cash flows used in financing activities was €25.9 million for the nine months ended September 30, 2022 (compared to €307.3 million generated from financing activities for the nine months ended September 30, 2021). For the nine months ended September 30, 2022, cash raised from new borrowings amounted to €12.4 million while the loan repayments and the payment of the principal portion of lease liabilities amounted to €19.9 million and to €4.9 million, respectively. Dividends distributed amounted to €13.5 million.

#### *Net change in cash and cash equivalents*

The net change in cash and cash equivalents was €(56.9) million for the three months ended September 30, 2022, compared to €326.4 million for the three months ended September 30, 2021.

The net change in cash and cash equivalents was €(156.4) million for the nine months ended September 30, 2022, compared to €309.8 million for the nine months ended September 30, 2021.

### Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Group is exposed to the following financial risks connected with its operations:

- financial market risk, mainly relating to foreign currency exchange rates and to interest rates;
- liquidity risk, with particular reference to the availability of funds and access to the credit market, should the Group require it, and to financial instruments in general; and
- credit risk, arising both from its normal commercial relations with customers, and its financing activities.

These risks could significantly affect our financial position, results of operations and cash flows, and for this reason we identify and monitor them, in order to detect potential negative effects in advance and take the necessary action to mitigate them, primarily through our operating and financing activities and if required, through the use of derivative financial instruments.

The following section provides qualitative and quantitative disclosures regarding the effect that these risks may have upon us. The quantitative data reported in the following section does not have any predictive value.

#### *Financial market risks*

Due to the nature of our business, we are exposed to a variety of market risks, including foreign currency exchange rate risk and, to a lesser extent, interest rate risk.

Our exposure to foreign currency exchange rate risk arises from our global footprint (both in terms of production and commercialization), as in some cases we sell our products in the currencies of the destination markets, which may differ from the currency of the countries in which the Group operates.

Our exposure to interest rate risk arises from the need to fund certain activities and the possibility to deploy surplus funds. Changes in market interest rates may have the effect of either increasing or decreasing our net profit/(loss), thereby indirectly affecting the costs and returns of financing and investing transactions.

These risks could significantly affect our performance and are therefore identified and monitored. We have in place various risk management policies, which primarily relate to foreign exchange, interest rate and liquidity risks.

In particular, to manage foreign exchange rate risk, we have adopted a hedging policy. Hedging activities are mainly executed at the corporate level, based on the information provided by the reporting system and utilizing instruments and policies conforming to IFRS. Hedging is undertaken to ensure protection in case an entity has transactions in currencies other than the one in which it primarily does business, also taking account of budgeted future revenues and costs. Despite hedging operations, sudden movements in exchange rates or erroneous estimates may result in a negative impact, although limited, on our results.

#### *Information on foreign currency exchange rate risk*

We are exposed to risk resulting from fluctuations in foreign currency exchange rates, which can affect our earnings and equity. In particular:

- Where a Group company incurs costs in a currency different from that of its revenues, any change in foreign currency exchange rates can affect the operating results of that company.
- The main foreign currency to which we are exposed is the U.S. Dollar for sales in the United States and other markets where the U.S. Dollar is the reference currency, against the Euro, Mexican Peso and Renminbi. Other significant exposures included the exchange rate between the Euro and the following currencies: Renminbi, Mexican Pesos, Japanese Yen and Danish Krone. It is our policy to use derivative financial instruments (primarily forward currency contracts, currency swaps, currency options and collar options) to hedge against exposures.
- Several subsidiaries are located in countries that are outside the Eurozone, in particular the United States, China, Japan, Mexico, Denmark, Brazil and Switzerland. As our reporting currency is the Euro, the income statements of those companies are translated into Euros using the average exchange rate for the period and, even if revenues and margins are unchanged in local currency, changes in exchange rates can impact the amount of revenues, costs and profit as restated in Euros. Similarly, intercompany financing may lead to foreign exchange rate impact due to different functional currencies.

- The assets and liabilities of consolidated companies that report in a currency other than the Euro may vary from period to period as a result of changes in exchange rates. The effects of these changes are recognized directly in equity as a component of other comprehensive income/ (loss) under gains/ (losses) from currency translation differences.

We monitor our main exposures with regard to translation exchange risk, whereby fluctuations in the exchange rates of a number of currencies against the consolidation currency may impact the consolidated financial statement values, although there was no specific hedging in this respect at September 30, 2022.

Exchange differences arising from the settlement of monetary items are recognized in the consolidated income statement within the net financial income/ (expenses) line item.

The impact of foreign currency exchange rate differences recorded within financial income/ (expenses) for the nine months ended September 30, 2022, except for those arising from financial instruments measured at fair value, amounted to net gain of €6.0 million (compared to €2.9 million net losses for the nine months ended September 30, 2021).

There have been no substantial changes in the third quarter of 2022 in the nature or structure of exposure to foreign currency exchange rate risk or in the Group's hedging policies.

We actively hedge against economic-transactional risk; more specifically, forward and swap contracts, plain vanilla and collar options are used to manage the exposures. Such instruments are not currently designated as cash flow hedges and contracts are entered for a period consistent with the underlying transactions, generally ranging from three to twelve months.

#### *Information on interest rate risk*

This risk stems from variable rate loans, for which sudden or significant interest rate fluctuations may have a negative impact on economic results. The monitoring of this risk is carried out at the corporate level and utilizes similar structures as those employed for the management of currency risks. We have hedges in place against interest rate risk, covering nearly all the loans contracted. Due to these operations, we have established a substantially fixed rate at improved conditions compared to the previous loans.

Our most significant floating rate financial assets at September 30, 2022, are cash and cash equivalents and certain financial current investments.

The risk arising from the net investments in foreign subsidiaries is monitored; no active hedging is currently being performed. With regard to commodity risk, we enter into fixed-price contracts for certain utilities.

#### *Liquidity risk*

Liquidity risk arises if we are unable to obtain the funds needed to carry out our operations under economic conditions. The main determinant of our liquidity position is the cash generated by or used in operating and investing activities.

From an operating point of view, we manage liquidity risk by monitoring cash flows and keeping an adequate level of funds at our disposal. The main funding operations and investments in cash and marketable securities of the Group are centrally managed and supervised by the treasury department with the aim of ensuring effective and efficient management of our liquidity. We undertake medium and long-term loans to fund medium and long-term operations. We undertake a series of activities centrally supervised with the purpose of optimizing the management of funds and reducing liquidity risk, such as:

- centralizing liquidity management;
- centralizing cash through cash pooling techniques;
- maintaining a conservative level of available liquidity;
- diversifying sources of funding of medium and long-term financing;
- obtaining adequate credit lines;
- monitoring future liquidity requirements on the basis of budget forecast and cash flow planning; and

- monitoring covenants on indebtedness.

Intercompany financing is conducted at arm's length terms and normally involves the holding company. These measures currently sufficiently guarantee, under normal conditions and in the absence of extraordinary events, the degree of flexibility required by movements of working capital, investing activities and cash flows in general.

We believe that our total available liquidity (defined as cash and cash equivalents plus undrawn committed credit lines and marketable securities), in addition to funds that will be generated from operating activities, will enable us to satisfy the requirements of our investing activities and working capital needs and ensure an appropriate level of operating and strategic flexibility. We, therefore, believe there is no significant risk of a lack of liquidity.

#### *Credit risk*

Credit risk is the risk of economic loss arising from the failure to collect a receivable. Credit risk encompasses the direct risk of default and the risk of a deterioration of the creditworthiness of the counterparty. The maximum credit risk to which we are theoretically exposed is represented by the carrying amounts of the financial assets stated in the consolidated statement of financial position sheet.

Where customers fail to meet payment deadlines, our financial position may deteriorate. Socio-political events (or country risks) and the general economic performance of individual countries or geographical regions may also assume significance in this respect. The credit risk is however mitigated by consolidated commercial relations with well capitalized multinational pharmaceutical and biologics companies and our guidelines created for the selection and evaluation of the client portfolio, which may require, where possible and appropriate, further guarantees from customers. As of September 30, 2022, our day's sales outstanding increased by 5.5 to 66, compared to 71.5 days as of December 31, 2021.

Trade receivables as of September 30, 2022, amounting to €204.2 million (compared to €165.3 million as of December 31, 2021) are shown net of the allowance for doubtful accounts amounting to €6.7 million (compared to €6.5 million as of December 31, 2021).

#### **Critical Accounting Policies and Significant Judgments and Estimates**

The Consolidated Financial Statements are prepared in accordance with IFRS which require Management's use of estimates and assumptions that may affect the carrying amount of assets, liabilities, income and expenses in the financial statements, as well as the disclosures in the notes concerning contingent assets and liabilities at the balance sheet date. Uncertainty about these assumptions and estimates could result in outcome that require material adjustments to the carrying amount of assets or liabilities affected in future periods.

Estimates are based on historical experience and other factors. The resulting accounting estimates could differ from the related actual results. Estimates are periodically reviewed and the effects of each change are reflected in the consolidated statement of profit or loss or in the consolidated statement of comprehensive income in the period in which the change occurs.

#### *Revenue Recognition*

We operate in several jurisdictions and assess whether contracts with customers provide it with the right to consideration for the performance fulfilled based on legal assessment of applicable contracts and other sources of enforceable rights and obligations (i.e., local regulations). With regard to revenue from contracts with customers for contract work and contract assets and liabilities, application of the cost-to-cost method requires a prior estimate of the entire lifetime costs of individual projects, updating them at each balance sheet date. This entails assumptions that can be affected by multiple factors, such as the time over which some projects are developed, their high level of technology and innovative content, the possible presence of price variations and revisions, and machinery performance guarantees, including an estimate of contractual risks, where applicable. These facts and circumstances make it difficult to estimate the cost to complete projects and, consequently, to estimate the value of contract work in progress at the balance sheet date. The Group estimates variable considerations to be included in the transaction price for the sale of products with rights of return and volume rebates. The Group forecasts sales returns using the historical return data to project expected return percentages. These percentages are applied to determine the expected value of the variable consideration.

#### *Recoverable amount of goodwill*

The impairment test on goodwill is carried out by comparing the carrying amount of cash-generating units and their recoverable amount. The recoverable amount of a cash-generating unit is the higher of fair value, less costs to sell, and its value in use. This complex valuation process entails the use of methods such as the discounted cash flow method which uses assumptions to estimate cash flows. The recoverable amount depends significantly on the discount rate used in the discounted cash flow model as well as the expected future cash flows and the growth rate used for the extrapolation.

#### *Development costs*

The amortization of development costs requires management to estimate the life cycle of related products. Any changes in such assumptions would impact the amortization charge recorded and the carrying amount of capitalized development costs. The periodic amortization charge is derived after determining the expected life cycle of the related product. Increasing an asset's expected life cycle or its residual value would result in a reduced amortization charge in the consolidated income statement. The useful lives of our development costs are determined by management at the time of capitalization and reviewed annually for appropriateness and recoverability.

#### *Employee benefit liabilities*

Employee benefits, especially the provision for employee severance indemnities and other long-term incentives, are calculated using actuarial assumptions; changes in such assumptions could have a material impact on such liabilities.

#### *Leases*

We cannot readily determine the interest rate implicit in the lease; therefore, the incremental borrowing rate (IBR) to measure lease liabilities is used. The IBR is the rate of interest that we would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Group 'would have to pay', which requires estimation when no observable rates are available (such as for subsidiaries that do not enter into financing transactions) or when they need to be adjusted to reflect the terms and conditions of the lease (for example, when leases are not in the subsidiary's functional currency). We estimate the IBR using observable inputs (such as market interest rates) when available and are required to make certain entity-specific estimates (such as the subsidiary's stand-alone credit rating). We also determine the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group applies judgment in evaluating whether it is reasonably certain whether or not to exercise the option to renew or terminate the lease. That is, we consider all relevant factors that create an economic incentive for us to exercise either the renewal or termination.

#### *Provision for expected credit losses of trade receivables and contract assets*

We use a simplified approach in calculating estimated credit losses (ECLs) for trade receivables and contract assets, initially based on the Group's historical observed default rates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. Our historical credit loss experience and forecast of economic conditions may also not be representative of the customer's actual default risk in the future.

#### *Income tax expense (current and deferred)*

The consolidated Group is subject to various taxes in multiple jurisdictions. The determination of tax liabilities requires the use of assumptions with respect to transactions whose fiscal consequences are not yet certain at the end of the reporting period. Calculation of taxes on a global scale requires the use of estimates and assumptions based on the information available at the balance sheet date. The deferred tax asset realization is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible and the tax loss carry forwards are utilized.

Estimating future taxable income requires estimates about matters that are inherently uncertain and requires significant management judgment, and different estimates can have a significant impact on the outcome of the analysis.

**Item 4. Controls and Procedures**

There were no significant changes in our internal control over financial reporting during the nine months ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



## PART II—OTHER INFORMATION

### Item 1. Legal Proceedings

The Company is from time to time subject to various litigation and administrative and other legal proceedings, including potential regulatory actions, incidental or related to our business, including commercial contract and tortious liability claims, among others (collectively “Legal Proceedings”).

Management believes that the outcome of the current Legal Proceedings will not have a material effect upon our business, financial condition, results of operations, cash flows, as well as the trading price of our securities. However, management’s assessment of Legal Proceedings is ongoing, and could change in light of the discovery of additional facts with respect to Legal Proceedings pending against the Company, not presently known to us, or determinations by judges, arbitrators, juries or other finders of fact or deciders of law which are not in accord with management’s evaluation of the probable liability or outcome of such Legal Proceedings. From time to time, the Company is in discussions with regulators, including discussions initiated by the Company, about actual or potential violations of law in order to remediate or mitigate associated legal or compliance risks. As the outcomes of such proceedings are unpredictable, the results of any such proceedings may materially affect the Company’s reputation, business, financial condition, results of operations, cash flows or the trading price of its securities.

### Item 1A. Risk Factors

There have been no material changes from the risk factors described in the Company's Annual Report on Form 20-F/A for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission on April 5, 2022.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

### Item 3. Defaults Upon Senior Securities

None.

### Item 5. Other Information

None.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Stevanato Group S.p.A.**

Date: November 8, 2022

By: /s/ Franco Moro  
Name: Franco Moro  
Title: Chief Executive Officer and Chief Operating Officer

